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Abstract 
 
PPARγ is the receptor for thiazolidinedione (TZD) anti-diabetes drugs, and a 
key regulator of adipose differentiation and insulin sensitivity. Increased heart 
failure associated with specific TZDs has reduced their clinical use. However 
recent work suggested that phosphorylation of PPARγ at Ser273 modified its 
response to TZDs, shifting the risk-benefit ratio of these drugs. Cyclin 
dependent kinase-5 (CDK5) which requires a non-cyclin partner (p35) for 
activity was proposed to phosphorylate Ser273, while obesity promoted 
cleavage of p35 to p25 thereby enhancing CDK5 phosphorylation of PPARγ 
(Choi et al2010). However the sequence surrounding Ser273 is not a CDK5 
consensus, therefore I have analysed PPARγ phosphorylation more carefully. I 
mutated Ser273 on PPARγ to alanine and compared phosphorylation of mutant 
and wild-type by multiple protein kinases. I raised a phosphospecific antibody to 
Ser273 of PPARγ and used this to monitor phosphorylation of PPARγ 
isoforms.P35-CDK5 and p25-CDK5 phosphorylate wild-type and S273A PPARγ 
to similar levels in vitro. The phosphospecific Ser273 antibody did not detect 
phosphorylation of endogenous PPARγ in adipose tissue of rats (with or without 
obesity). I could not detect phosphorylation of Ser273 on recombinant PPARγ 
when over-expressed in HEK293 or 3t3-L1 cells (± differentiation). Finally, 
phospho-Ser273 was not present on PPARγimmunoprecipitated from adipose 
tissue (obese and non-obese), or from cell lines, as assessed by 
phosphopeptide analysis or immunoblot. I have tried multiple approaches to 
validate that CDK5 phosphorylates Ser273 of PPARγ but our data questions the 
clinical potential of targeting this modification. 
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Chapter1 – Introduction 
 
1.1 Glucose Homoeostasis 
Homeostasis is the process by which the body maintains a constant internal 
environment by changing physiological responses (Barnett 2008). Glucose 
regulation is one of the many homeostatic processes that occurs within the 
body, with others including regulation of water concentration, temperature and 
pH.The liver, brain, pancreas, intestine, muscle and adipose tissue are the 
major organs involved in the management of energy metabolism; these organs 
communicate with each other to sense the energy status of the entire organism 
and coordinate their function (Feinglos and Bethal 2008). 
 
It is important that glucose levels are maintained as glucose is the primary 
source of energy for the body’s cells. Glucose is kept in a narrow range 
between 3mM after prolonged fasting or exercise, and maximum values of 
9mMafter a meal. Homoeostasis of glucose is crucial so that hyperglycaemia 
and hypoglycaemia do not occur; hyperglycaemia is when there is a higher than 
normal amount of blood glucose present and hypoglycaemia is when blood 
sugar levels are too low. Hyperglycaemia can result in non-enzymatic 
glycosylation and thus the loss of protein function, as well as glucose induced 
oxidative damage. Hypoglycaemia leads to an under supply of glucose to 
tissues and can thus be a danger for neuronal cells, fibroblasts and 
erythrocytes, which use glucose as the main energydelivering fuel when under 
normal physiological conditions(König,Bulik and Holtzhütter 2012). 
 
When food is consumed, also known as the fed state, the pancreatic beta cells 
secrete the hormone insulin, which instructs the body to store fuel. Insulin 
promotes the deposition of glycogen in the liver, activates glucose transport and 
glycogen synthesis in muscle and promotes triglyceride accumulation in the 
adipose tissue;it does this by inhibitingketogenesis in the liver, proteolysis in the 
muscle and lipolysis in adipose tissue (Taylor 1999).Insulin binds to its receptor, 
initiates a protein kinase cascade (see section 1.1.1) and stimulates glycogen 
synthesis via glycogenesis, as well as suppressing gluconeogenesis in the 
liver(Berg et al 2007).  
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When blood glucose levels begin to drop several hours after a meal, known as 
the fasting state, there is a decrease in insulin secretion and a rise in glucagon 
secretion;glucagon is secreted by the alpha cells of the pancreas in response to 
the low blood sugar levels, and it binds to the glucagon receptor within the 
plasma membrane. Glucagon mobilizes glycogen stores when there is no 
dietary intake of glucose, and the mobilized glycogen is broken down into 
glucose via a process known as glycogenolysis. Glucagon alsopromotes 
gluconeogenesisand suppresses glycolysis to increase the levels of glucose 
available (Berg et al2007). Another function of glucagon is that it promotes 
lipolysis, to break down the lipids stored as triglycerides in fat cells (Liljenquistet 
al 1974).Thus glucagon and insulin work as opposing factors but as their 
synthesis is reciprocally regulated by blood glucose they are generally not 
produced at the same time in healthy individuals. 
 
1.1.1 Liver in glucose homeostasis 
 
As described in section 1.1, the liverplays a crucial role in maintaining glucose 
and free fatty acid homeostasis. The liver buffers plasma glucose between net 
hepatic glucose utilization (HGU) and net hepatic glucose production (HGP), 
depending on if the plasma glucose levels have risen or fallen below the critical 
threshold value of 6mM. The switchbetween HGU and HGP is between a 
positive export of glucose and negative import of glucose to get a net hepatic 
glucose balance; in this process hepatic metabolism is altered from glucose 
production (glycogenolysisand gluconeogenesis)duringhypoglycaemia, to 
glucose utilization and storage(glycolysis and glycogen 
synthesis)duringhyperglycaemia.The hepatocytes are thus key for transient 
storage of glucose as glycogen, thesynthesis of glucose from glycerol, lactate 
and amino acids, and the conversion of excess glucose into triglycerides(König, 
Bulik and Holtzhütter 2012). 
 
1.1.2 Muscles in glucose homeostasis 
 
During exercise the uptake of glucose is required to provide a supply of fuel to 
the working muscles, and for after exercise it is needed for the replenishment of 
muscle glycogen stores (Sinacore and Gulve 1993).Skeletal muscle accountsfor 
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approximately 80–85% of peripheral glucose uptake, with the remaining 
proportion going to the rest of the body’s cells (Feinglos and Bethal 2008). 
 
Muscle lacks glucose 6-phosphatase, so glycogenolysis in muscle does not 
provide glucose for release into the blood. However in the fasting state, amino 
acids and other substrates are exported from the muscles to the liver,to 
generate glucose via hepaticgluconeogenesis (Taylor 1999). 
 
The entry of glucose into muscle cells isachieved by a carrier-mediated system 
with protein transport molecules; the two most common are GLUT-1 and GLUT-
4. GLUT-1 transporter is found in the sarcolemmalmembrane, and it is involved 
in glucose transportunder basal conditions. Upon insulin stimulation, glucose 
transport accelerates due to the translocation of GLUT-4from an intracellular 
pool out to thesarcolemmal membranes and T-tubule (Barnard and Youngren 
1992).Experiments in mice with muscle-specific GLUT4 deficiency showed 
decreased insulin responsiveness in adipose tissue and liver (Zismanet al 
2000), and those that were adipose-specific GLUT4 depleted showed muscle 
and liver insulin resistance (Abel et al 2001). The insulin resistance is thought to 
happen through elevated blood glucose levels occurring in the conditional 
knockout animals, which secondarily impairs insulin signalling (Kim et al 2001). 
 
1.1.3 Adipocytes and adipose tissue in glucose homeostasis 
 
Adipocytes are the major fat-containing component of adipose tissues. In 
mammals the two main types of adipose tissue are white adipose tissue and 
brown adipose tissue. White adipose tissue is present in many species, and is 
the main adipose tissue in humans. Brown adipose tissue functions primarily in 
thermogenesis, due tothe high number of iron-containing mitochondria present 
in the cells helping dissipate energy in the form of heat (Wu, Cohen and 
Spiegelman 2013). 
 
Recent research has shown a third type of adipocyte known as beige or brite 
adipocytes; these are brown adipocytes that appear in white adipose tissue that 
derive from precursor cells that are different from those in classical brown 
adipose tissue. The beige adipocytes are thought to be involved in the trans-
differentiation between white to brown adipocytes, and to play a role of 
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thebrowning process in protection against obesity (Giralt and Villarroya 2013). 
The thermogenic process of beige and brown and fat cells can increase whole-
body energy expenditure and therefore is suggested they can protect against 
obesity and diabetes (Wu, Cohen and Spiegelman 2013). 
 
Adipocytes in white adipose tissue are highly specialized, with the crucial 
function of storage, metabolism, and release of lipids (Lazar 1999).Most energy 
stores in healthy humans are contained within the adipose tissue (Rosen and 
Spiegelman 2006).Adipose tissue stores energy in the form of triglycerides 
during nutritional excess and this energy can be mobilized by lipolysis, releasing 
fatty acids and glycerol into the circulation when required (Feinglos and Bethal 
2008). 
 
Adipose tissue is also an endocrine organ, as it synthesizes and secretes the 
biologically active adipokines that affect various homeostatic systems; these 
include tumour necrosis factor alpha (TNF-α) and leptin, which are elevated 
during obesity (Gregoire, Smas and Sul 1998). In adipose tissue liopogenesis 
(lipid storage), and lipolysis (lipid utilization), are regulated by several 
hormones, whichrequire the presence of key transcription factors such as 
peroxisome proliferator-activated receptors, sterol regulatory element-binding 
proteins, and enzymes, such as fatty acid synthase and 
carnitinepalmitoyltransferase (Lee 2012).  
 
Excess adipocyte mass is thedefining feature of obesity, a condition that is 
closely linked to other diseases such as hypertension, atherosclerosis, cancer, 
gallbladder disease, and type 2 diabetes (Gregoire, Smas and Sul 
1998).Adipocytes derive from fibroblast-like precursor cells, which are 
differentiated by a timed cascade of transcriptional events, withperoxisome 
proliferator activated receptor gamma (PPARγ) central to this process. PPARγ 
is activated by natural fatty acid derivatives including eicosanoids, as well as 
compounds such as the anti-diabetic thiazolidinedione class of drugs (Lazar 
1999 and see later).  
 
1.1.4 Insulin signalling pathway 
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Insulin triggers the uptake of glucose, fatty acids and amino acids into liver, 
muscle an adipose tissue, as well as promoting the storage of these nutrients in 
the form of glycogen, proteins and lipids (Saltiel and Pessin 2007).It binds to its 
receptor and triggers the activation of a signalling pathway that stimulates the 
transport of nutrientsfrom the blood supply to tissues and promotes the 
conversion of these nutrients into storage macromolecules (Lizcano and Alessi 
2002). A diagram of theinsulin signalling pathway is shown in figure 1.1, 
showing the key components and phosphorylation pathways 
 
Figure 1.1- Diagram illustrating the different stages of the insulin signaling pathway 
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The insulin receptor is a complex that consists of two extracellular 
alphasubunits, which bind insulin, andtwo trans-membrane beta subunits that 
have tyrosine kinase activity. Insulin binding to the alpha subunit induces the 
phosphorylation of onebeta subunit by another on specific tyrosine residues in 
an activationloop; the receptor also undergoes auto-phosphorylation at 
othertyrosine residues in the juxta-membrane regions and intracellulartail 
(Chang, Chiang, Saltiel2004). 
 
The activated insulin receptor can then phosphorylate tyrosine residues on 
intracellular substrates by recognition of the residues by the phospho-tyrosine 
binding domain of adaptor proteins; these include the insulin receptor substrate 
(IRS) family, Growth Factor Receptor-Bound Protein 2(GRB-2)and signal 
regulatory protein family members.The phospho-tyrosine residues in the 
proteins then interact via SrcHomology 2 (SH2) domains with adapter subunits 
of signalling intermediates, includingphosphatidylinositol 3-kinase (PI 3-kinase) 
(Chang, Chiang, Saltiel2004). 
 
The catalytic subunit of PI 3-kinase then phosphorylates phosphatidylinositol 
(4,5) bisphosphate, which then leads to the formation of Ptd(3,4,5)P3.  A major 
downstream effector of Ptd(3,4,5)P3 is AKT, which when activated requires the 
protein kinase 3-phosphoinositide-dependent protein kinase-1 (PDK1). 
Activated AKT can then enter the cytoplasm,where it phosphorylates and 
inactivates glycogen synthase kinase 3 (GSK3).Glycogen synthase is a major 
substrate of GSK3, and it is an enzyme that catalyses the final step in glycogen 
synthesis; therefore the inactivation of GSK3 by AKT promotes glucose storage 
as glycogen(Lizcano and Alessi 2002).Activation of the mitogen activated 
protein (MAP) kinase pathway occursthrough Ras activation, withSyp 
modulating the MAP kinase and other effector pathways(Holman and Kasuga 
1997). 
 
As well as promoting glucose storage, insulin inhibits the production and 
release of glucose by the liver by blocking gluconeogenesis and glycogenolysis 
(Saltiel and Kahn 2001). Insulin directly controls the activities of a set of 
metabolic enzymes by phosphorylation and dephosphorylation events, and by 
23 
 
regulating the expression of genes that encode for hepatic enzymes involved in 
gluconeogenesis (Schmollet al2000). 
 
Protein tyrosine Phosphatases (PTPases) catalyze the dephosphorylation of 
insulin receptor and its substrates, leading to a reduced effect of insulin action. 
PTPasesare linked to being negative regulators of insulin signaling, including 
protein-tyrosine phosphatase 1B (PTP1B), phosphatase and tensin homolog 
deleted on chromosome-10 (PTEN) and SH2-containing Inositol Phosphatase-2 
(SHIP2).Over-expression of SHIP2 decreases insulin-stimulated Akt activation, 
GSK3 inactivation, and glycogen synthase activation (Wolf et al 1995).Any 
defects in the insulin signalling pathway can contribute towards diabetes, and 
due to there being so many stages within the insulin pathway that can go 
wrong, and there is a lot of research investigating these pathways for 
therapeutic potential for the treatment of type 2 diabetes. 
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1.2 Diabetes Mellitus 
 
Diabetes Mellitus is described by Tuch, Dunlop and Proietto (2000),as a 
disorder ‘characterized by the presence of an excess of glucose in the blood 
and tissues of the body’. The history of diabetes dates back to the ancient 
Egyptians in 1550BC, with an Egyptian papyrus thought to be the first 
reference, mentioning a rare disease that caused a patient to lose weight 
quickly and urinate frequently. The first clinical description of diabetes was 
given by the Ancient Greek physician Aretaeus in 30-90CE, with symptoms 
recorded such as thirst, weight loss and frequent urination. In 131-201CE, 
Galen hypothesized that it was a disease of the kidney (DIABETES 2014).The 
origin of Diabetes Mellitus is a Greek and Latin phrase, which translates as 
diabetes being the Greek for siphon, referring to an excess quantity of urine 
being discharged, and mellitus being the Latin for honey; thus the literal 
meaning is the passage of large amounts of sweet urine (Tuch, Dunlop, and 
Proietto2000).  When the body has an inability to produce insulin, or fails to 
uptake and store nutrients due to defects in the insulin signalling pathway (see 
section 1.14), diabetes (plasma hyperglycaemia) is the result. 
 
The two main types of diabetes are type 1 and type 2. Type 1diabetes is an 
autoimmune disease, which results in almost complete loss of the pancreatic 
beta cells that are the sole site of insulin production in the body. Therefore 
hyperglycaemia in Type 1 diabetes is due to a lack of insulin production and is 
often referred to as insulin dependent. Type 2diabetes is a more complex 
multifactorial disorder primarily caused by the body’s ineffective response to 
insulin, or insulin resistance (WHO 2012); type 2 diabetes is the more common 
form, accounting for roughly 85% of the total diabetes burden. In the UK alone, 
there are currently 2.9 million people that have been diagnosed with diabetes, 
alongside an estimated 850,000 people who have the condition but are 
unaware of this fact (Diabetes UK 2012). 
 
There are many signs and symptoms associated with diabetes, but the main 
symptoms are an increase in thirst, and an increase in the need to urinate; other 
symptoms may include weight loss, tiredness, mood swings and nausea.  The 
symptoms of type 1 diabetes develop very quickly, over a matter of weeks, 
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whereas the symptoms of type 2 diabetes are harder to recognise as they 
develop slowly over time (Diabetes UK 2012). The diagnosis of diabetes 
requires two separate measures of fasting blood glucose being greater than 
7mM, with fed blood glucose levels above 11mM. 
 
There is no defined cause of diabetes, and this area is still under research, with 
many current theories. There are influences fromboth genetics, and 
environment (including lifestyle choices such as diet and exercise). While type 1 
diabetes is due to loss of the pancreatic beta cells that produce insulin, the 
causes of type 2 diabetesare multi-factorial, including obesity, sedentary 
lifestyle and aging(Diabetes UK 2012). Type 2 diabetes Mellitus (T2DM) affects 
5% of the population (Juresa and Metelko 2009),and is described as ‘an 
insidious chronic disease’, that has an increasing prevalence each year due to 
the global waistline expanding (Whitehead 2011).It is a heterogeneous disorder 
that is caused by concomitant impairment of insulin secretion by pancreatic beta 
cells, and of insulin action in peripheral target tissues (Fiume et al 2011).The 
disease itself is associated with disturbances of carbohydrate, fat and protein 
metabolism, and cardiovascular risk factors, such as insulin resistance, obesity, 
hypertension, dyslipidemia, and atherosclerosis (Tontonoz and Spiegelman 
2008); therefore much focus is on understanding the connection between 
obesity, T2DM and cardiovascular disease. 
 
It is possible to have diabetes without being obese, but there are very strong 
links between the 2 diseases. Under normal conditions, the pancreatic islet β-
cells increase insulin release sufficiently to overcome the reduced efficiency of 
insulin action, therefore maintaining normal glucose tolerance. For obesity and 
insulin resistance to be associated with type 2 diabetes, the β-cells must be 
unable to compensate fully for decreased the insulin sensitivity. Some people 
can have β-cell dysfunction with normal glucose levels, due to them having a 
high risk ofdeveloping the disease (Kahn et al 2006). 
 
In obese individuals, adipose tissue secretes increased amounts of non-
esterified fatty acids, hormones, glycerol, pro-inflammatory cytokines and 
factors involved in the development of insulin resistance.  
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Excessive secretion(or reduced storage) of free fatty acids and altered 
production of adipokines from adipose tissue arelikely contributors to insulin 
resistance in the peripheral tissues (Steppan C. M et al 2001). Polypeptides 
such as leptin, adiponectin and tumour necrosis factor alpha (TNF-α), which are 
secreted by adipocytes, have been shown to affect insulin actionon other 
tissues.  An increase in plasma free fatty acids (FFAs) causes lipotoxicity in the 
non-adipose tissues such as the liver, pancreas and skeletal muscle, and this 
reduces glucose disposal, increases gluconeogenesis and impairs insulin 
secretion (Gross and Staels 2007).  
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1.3 Treatment of Diabetes 
There are many current treatments available for T2DM; these consist 
ofbiguanides, sulphonylureas, meglitindines, thiazolidinediones, alpha 
glucosidase inhibitors, incretinsand insulin therapy.  One of the most common 
oral treatments is metformin, a biguanide drug, which seems toimprove insulin 
action and exert insulin dependent effects. Thesulphonylureas, incretins and 
meglitinides work by stimulating insulin secretion, whereas alpha glucosidase 
inhibitors slow down the rate of carbohydrate digestion. A new group has also 
emerged known as SGLT2 inhibitors, and these work by decreasing glucose 
absorption in the kidneys so more is excreted in the urine. The final group of 
drugs, thethiazolidinediones, improves insulin action via induction of the 
transcription factor peroxisome proliferator activated receptor gamma (PPARγ) 
which is a key regulator of adiposity(Barnett 2008, Lehmann 1995).Many of 
these drugs have side effects such as weight gain, or may not be suitable for 
each patient, so alternatives need to be sought, alongside an exercise and diet 
plan (Diabetes UK 2013). My project investigates regulation of PPARγ, and the 
mechanism of action of the thiazolidinedione drugs. 
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1.4 Peroxisome Proliferator-Activated Receptors 
1.4.1 Background 
Peroxisome proliferator-activated receptors (PPAR) are ligand activated 
transcription factors that are part of the nuclear receptor family. The name 
originates from the fact that ligandssuch as fibrates can induce the proliferation 
of intracellular peroxisomes; while their biological roles include control of 
differentiation, proliferation and metabolism of glucose, lipids and 
proteins(Juresa and Metelko 2009).They share a high degree of structural 
homology with the other members of the nuclear receptor family, especially in 
the DNA binding domain and ligand and cofactor binding domains (Michaliket al 
2006).PPARs exist as heterodimers with a retinoid X receptor (Berger and 
Moller 2002), and upon ligand activation the dimer modulates transcription via 
binding to a specific DNA sequence element, the peroxisome proliferator 
response element (PPRE), in the promoter region of target genes (Michaliket al 
2006). 
 
There are three isoforms of PPAR, peroxisome proliferator-activated receptor 
alpha (PPARα), peroxisome proliferator-activated receptor beta(PPARβ), and 
peroxisome proliferator-activated receptor gamma (PPARγ); the first to be 
discovered was PPARα in 1990 (Evans, Barish and Wang 2004). Each PPAR 
isoform has a different set of target genes, ligands, biological functions, and 
different tissue expression profile(Juresa and Metelko 2009, Burns and 
Huvel2007). PPARα is highly expressed in hepatocytes, proximal tubes of the 
kidney, enterocytes and cardiomyocytes, all of which oxidise fatty acids. 
PPARβ, also known as PPARδ, is expressed ubiquitously, and PPARγ is 
predominantly expressed in adipose tissue. 
 
PPARα plays a key role in energy homeostasis.During a fasting stage, fatty 
acids are released from adipose tissue and transported into the liver, where 
PPARα is robustly induced; this promotes hepatic fatty acid oxidation to 
generate ketone bodies and provides an energy source for peripheral tissues. 
Fibrates are PPARα selective agonists, and they are widely used to treat 
hypertriglyceridemia(Evans, Barish and Wang 2004). PPARβ also regulates 
energy homeostasis but also has an influence on placental and gut 
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development.PPARβ is the least understood of the PPARs, but PPARβ 
selective agonists have been found to increase HDL-C levels in diabetic mice 
(Berger, Akiyama andMeinke 2005). PPARγ is crucial for adipose tissue 
differentiation (Michaliket al 2006),and recent work has linked obesity and 
PPARγ phosphorylation to the regulation of PPARγ transcriptional activity and 
response to ligands (Choi et al 2010). 
 
1.4.2PPARγ 
PPARγ was initially characterized as the master regulator for the development 
of adipose cells(Tontonoz and Spiegelman 2008). It exists as two distinct 
isoforms, namely γ1 and γ2,which arise by differential transcription start sites 
and alternativesplicing (Burns and Huvel 2007); PPARγ2 is 30 amino acids 
longer at the N Terminus. The C-terminus of PPARγ contains the ligand binding 
pocket, which includes the AF2 domain that is important for the docking of co-
activator proteins. The N terminus of PPARγ is the target for upstream 
regulatory pathways(Tontonoz and Spiegelman 2008). PPARγ2 is found at high 
levels in adipose tissues, while PPARγ1 is expressed more broadly, extending 
to the gut, brain, vascular cells, and specific kinds of immune and inflammatory 
cells(Michaliket al 2006). 
 
1.4.3 Functions of PPARγ 
1.4.3.1 Upstream regulationof PPARγ 
The biological functions of PPARγ are wide ranging, but it is best known as a 
master transcriptional regulator of lipid metabolism, being required for adipocyte 
differentiation and modulating triglyceride accumulation in adipocytes (Distelet 
al 1987)(Ye 2011, Jones et al 2005). PPARγ expression is induced during the 
differentiation of pre-adipocytes into adipocytes (Lazar 1999), and its 
expression is enriched in both brown and white adipose tissue.Glucocorticoids 
will induce expression of C/EBP-δ promoting formation of C/EBP-δ -C/EBP-β 
heterodimers and transcriptional activation of the PPARγ gene (Gregoire, Smas 
and Sul 1998). Signalling pathways such as the hedgehog, Wnt pathways, 
C/EBPβ and -δ, and EBFs are upstream of PPARγ.Hormonal treatment of pre-
adipose cells induces C/EBP-β and –δ, and this causes them to bind to 
thePPARγ promoter and induce PPARγ(Tontonoz and Spiegelman 2008). 
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PPARγ has many synthetic and biological ligands and 
modifiers.Thiazolidinediones (TZDs), or glitazones, comprise a class of 
compounds that reverse insulin resistance and improve the symptoms of type 2 
diabetes, possiblythrough specific activation of PPARγ (Gross and Staels 2007, 
Lehmann 1995).However TZDs have side effects, such as oedema and weight 
gain; this restricts the use of TZDs, so alternativesto TZDwhich still induce 
PPARγ activity but with less side effects are being sought, (Gross and Staels 
2007); these include regulators of SIRT1, CREB, nitrous oxide, p38, ERK and 
CDK5. The key endogenous ligands of PPARγ are not yet fully known 
(Tontonoz and Spiegelman 2008). Natural ligands including fatty acid and their 
derivatives, such as eicosanoids, fatty acids and eicosanoid derivatives,can 
activate PPARγ at micro-molar concentrations(Ye 2011).My project aimed 
todecipher how phosphorylation of PPARγ affects its regulation and/or activity. 
 
1.4.3.2 Downstream actions of PPARγ 
The activation of PPARγ promotes adipocyte differentiation through the 
induction of target genes that are involved in energy homeostasis (Kota, Huang 
and Roufogalis 2005); these include GLUT4 and PEPCK which are important 
for glucose and triglyceride uptake and storage (Tontonoz and Spiegelman 
2008 and Kota, Huang and Roufogalis 2005), as well as many adipose specific 
genes. 
 
Activation of PPARγ in adipose tissue improves its ability to store lipids and 
subsequently to reducelipotoxicity in muscle and liver. PPARγtarget genes 
encode molecules that promotelipogenesis and lipid storage; these include 
lipoprotein lipase(hydrolysis of lipoproteins), FATP-1 (fatty acid transporter), 
aP2 (fatty-acidbinding protein), CD36 (receptor for lipoproteins), glycerolkinase, 
and SCD-1 and SREBP-1 (regulators of sterol and fatty acidsynthesis and 
sterol). The lipid re-partitioningto increase the triglyceride contentof adipose 
tissuelowers free fatty acids and triglycerides in the circulation, liver and muscle; 
due to this there is an improved insulin sensitivity of these tissues (Evans, 
Barish and Wang 2004). 
 
Drugs that target PPARγ alter the release of adipokines from fat, including TNF-
α, leptin, resistin and adiponectin; these moleculeshave multiple metabolic 
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effects in other tissues in the body. TNF-α and resistin promote insulin 
resistance, but their expression is inhibited by PPARγ agonists. Concurrently, 
PPARγagonists stimulate the production of molecules such as adiponectin, 
which promotesfatty acid oxidation and insulin sensitivity in muscle and liver; as 
a result of this hepatic glucose production is reduced and muscle glucose use is 
increased. The PPARγ-adiponectinpathway can induce the activity of AMP-
activated protein kinase, the energy sensor of the cell. This protein kinase may 
well be a key player in the beneficial effects of PPARγ agonists on glucose 
metabolism and as such represents a possible pharmacologic target for type 2 
diabetes mellitus (Evans, Barish and Wang 2004). 
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1.5 Regulation of PPARγ Phosphorylation 
1.5.1 Protein kinases 
Protein kinases are enzymes that can transfer a phosphate group from a high-
energy phosphate, usually adenosine triphosphate (ATP), to polypeptide, 
usually to serine, threonine or tyrosine residues (Daintith and Martin 2005). 
Protein phosphorylation mediatesa large partof signal transduction in eukaryotic 
cells and by modifyingkinase-substrate interactions hormones and growth 
factors control many cellular processes that include metabolism, transcription, 
cytoskeletal rearrangement, cell movement, cell cycle progression, 
differentiation and apoptosis.  
 
There are eight main human protein kinase families as defined by their primary 
structure (Fig 1.2). The main groups linked to insulin and glucagon action are 
the AGC (contains PKA, PKG, PKC families), CMGC (contains CDK, MAPK, 
GSK3, CLK families)and CAMK (calcium/calmodulin-dependent protein 
kinases)families, while cell cycle, apoptosis and cell growth are associated with 
activity of the CMGC family; there is also a small group known as the atypical 
protein kinases that do not containsufficient sequence homology to the other 
protein kinases within the catalytic core to suggest they would code for an 
active enzyme. The CMGC kinases, which contain cyclin-dependent kinases 
(CDKs), CDK-like kinases, glycogen synthase kinases (GSK), and mitogen-
activated protein kinases (MAP kinases) (Fig 1.1), were of particular interest to 
my work as certain members of this group have previously been proposed to 
phosphorylatePPARγ (Adams et al 1997 and see below).  
 
AMPK has also been shown to be involved with PPARγ, being a key 
downstream target of the PPARs. It is an important regulator in energy 
metabolism, and overall, the effects of PPAR agonists on AMPK-mediated 
metabolic functions may contribute to the recovery of insulin sensitivity or 
treatment of metabolic syndrome (Lee and Kim 2010). AMPK plays a role in 
suppressing the expression of PPARγwhilst increasing adipocyte specific genes 
that are up-regulated by PPARγ;activation of PPARγimproves insulin sensitivity, 
whereasmoderate reduction of PPARγ activity also improves it. Fasting has 
been shown to cause an elevated AMP/ATP ratio and activatedAMPK activity 
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inadipose tissue, and AMPK shown to be involved in thefasting-induced gene 
regulation of adipocytes (Kajitaet al 2008). 
 
Figure 1.2 –Diagram showing the human kinome map and the known kinase families 
(Manning 2002) 
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1.5.2 PPARγ phosphorylation and function 
 
PPARγ is a phospho-protein but as yet there are only a few reports of direct 
phosphorylation by specific protein kinases. Firstly,MAP kinaseswere found to 
phosphorylate PPARγ (Adams et al 1997), and this altered the transcriptional 
activity of both isoforms. ERK2 and JNK phosphorylated PPARγ1 at Ser84 and 
PPARγ2 at the homologous residue Ser112 (Adams et al 1997). PPARγ lacking 
this serine was transcriptionally enhanced both basally and in response to 
ligands, suggesting this phosphorylation was inhibitory. More recently the 
Pigment epithelium-derived factor (PEDF) induction of interleukin-10 expression 
in human macrophages was found to requirePPARγ and this regulation was 
blocked by an inhibitor of ERK (Yang et al 2010). In addition the ERK regulation 
of PPARγ was proposed as a therapeutic target in Alzheimer’s Disease 
(Denneret al, 2012). However these latter studies did not establish a role for 
direct phosphorylation of PPARγ by a MAP kinase. In addition the connection is 
further complicated by the fact that ERK2 signalling may also lie downstream of 
PPARγ (Chen et al 2006). The ERK2 regulation of PPARγ clearly requires 
further clarification.In other work PPARγ was reported to be a CDK7 substrate 
and again the residue targeted was the Ser84/Ser112 (Compeet al 2005). 
These studies also demonstrated that mutation of Ser84/Ser112 altered the 
transcriptional activity of recombinant PPARγ, and its response to ligands. 
 
More recently phosphorylation of PPARγ at Ser273 by CDK5 was reported by 
Choi et al(2011). They proposed that PPARγactivationwas controlled by CDK5 
phosphorylation at Ser273 (PPARγ1 sequence numbering), although this 
sequence does not resemble the consensus sequence for phosphorylation by 
this kinase. Mutation of Ser273 to a non-phosphorylatable alanine did not alter 
the adipogenic capacity of PPARγ, but rather modified the target gene profile in 
obesity, including increases in adiponectin, resistin and leptin mRNA (Choi et al 
2010). The authors showed that the phosphorylation of PPARγ by CDK5 in cells 
was blocked by PPARγ ligands, such as rosiglitazone and MRL24. PPARγ 
phosphorylation was induced by obesity associated factors (egTNFa, IL-6 and 
IL-10) at least in cultured 3t3-L1 cells, and this could be reduced by knockdown 
of CDK5 by RNAi. Moreover obesity was proposed to promote cleavage of the 
CDK5 regulatory subunit p35 to p25, which promotes movement of CDK5 
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fromthe membrane compartment to other parts of the cell including the nucleus 
(Fig 1.3), and increased PPARγ phosphorylation was reported in adipocytes 
from obese mice.Meanwhile preliminary evidence was presented to suggest 
that inhibition of PPARγ phosphorylation in obese patients by rosiglitazone was 
associated with the anti-diabetic effects of the drug; this data led the authors to 
propose that Cdk5-mediated phosphorylation of PPARγ may be involved in the 
pathogenesis of insulin-resistance, and that the CDK5 pathway provided an 
opportunity for an improved generation of anti-diabetic drugs that would act 
through regulation of PPARγ (Choi et al 2010). The same group has 
subsequently reported potent anti-diabetic actions of a novel non-agonist 
PPARγ ligand that works by interfering with Cdk5-mediated phosphorylation 
(Choi et al 2011). Importantly the authors indicate that their work provides an 
opportunity to develop ligands that would induce the insulin sensitizing actions 
of PPARγ without the unwanted side-effects of heart failure and oedema. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3– Proposed mechanism of phosphorylation of PPARγ by CDK5 and obesity, 
showing the cleavage of p35 to p25, the activation of CDK5 and phosphorylation of PPARγ 
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1.6 CyclinDependent Kinase 5, PPARγ and diabetes 
Spiegelman and colleagues have proposed that PPARγ is regulated by cyclin-
dependent kinase 5 (CDK5) during obesity to influence the development of 
diabetes (see above). Cyclin dependent kinases play an important role in the 
cell division cycle, and there are 21 genes encoding CDKs based on sequence 
similarity, with an additional five genes encoding for the more distant group of 
CDKL kinases(Malumbreset al 2009). These serine/threonine kinases share the 
unusual property of being inactive when not bound to a specificregulatory 
partner (Sharma et al 1999). 
 
CDK5 is ubiquitously expressed in mammals (Ahmed and Sharma 2011). 
However it is enrichedin neurons and unlike its related kinases, it does not 
appear to have a role in cell-cycle control.This is because the CDK5 partner 
proteins p35 or p39 are notcyclins, and thus CDK5 activity does not cycle during 
cell division.However it has been proposed that these regulatory subunits are 
targeted by various cytokines and inflammatory signals that are increased in 
obesity and type 2 diabetes(Whitehead 2011).The details of these regulatory 
signals remain unclear and how they may influence the proposed neuronal 
functions of CDK5, including axon guidance, cell survival, regulation of synaptic 
spine density and neuronal migration are also not yet known. Interestingly 
CDK5 phosphorylates the Alzheimer’s disease related protein tau and as such 
has been proposed as a potential drug target in neurodegeneration(Quet al 
2011). 
 
CDK5 is a proline-directed kinase meaning that it will onlyphosphorylate 
aserineorthreonine immediately upstream of a proline residue (Dhavan and Tsai 
2001). Studies using peptide substrates have suggested thatCDK5 also has a 
preference for a basic residue in the +3 position (ie consensus sequence 
(S/T)PX(K/H/R), where S/T isserine or threonine, X is any amino acid, and P is 
the proline in the +1 position (Songyang 1996).  
 
CDK5 in the pancreatic islet is proposed to regulate both glucotoxicity and 
insulin release (Ahmedand Sharma 2011).When CDK5 activity 
isoverexpressed, the overall effects include decreased rates of insulin release, 
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reduced insulin production and diminished insulin gene expression. Insulin 
secretion starts whencalcium enters the beta cell through the L-VDCC in 
response to an enhanced level ofextracellular glucose.CDK5phosphorylates 
loop II and III of the α1c subunit of L-VDCC restraining channel activity, thereby 
inhibiting glucose stimulated insulin secretion(Ahmed and Sharma 2011). 
 
1.7 Unanswered questions regarding regulation of PPARγby obesity and 
CDK5. 
 
PPARγ2has five possible Ser/Thr-Pro phosphorylation sites within its sequence 
(Fig 1.4) that CDK5 could phosphorylate, but none of these are particularly 
close to theproposed consensus (Songyang 1996), including Ser273, the site 
proposed to influence obesity induced diabetes. None have the basic residues 
that enhance CDK5 phosphorylation, at least in vitro. In addition much of the 
data on PPARγ phosphorylation in cells was obtained using an antibody raised 
against a consensus CDK5 phosphorylation motif, so it remains possible that 
this antibody detects more than Ser273 phosphorylation. Importantly, Choi et al 
did not provide an assessment of phosphorylation stoichiometry or comparison 
of PPARγ phosphorylation with that of other CDK5 substrates, or by other 
CMGC kinases, such as ERK2 and CDK7 (see earlier). Studies with a 
Ser273Ala mutant PPARγ indicate changes in transcriptional function of this 
factor however this does not necessarily indicate that CDK5 is the only or even 
the major Ser273 kinase (or in fact that it is only loss of phosphorylation that 
mediates the difference in function of the mutant). Finally, it seems that if 
obesity altered CDK5 regulation that there would be many additional 
physiological effects on CDK5 function, since this is a relatively ubiquitous 
protein kinase and is known to regulate neuronal and pancreatic biology. 
 
As such my project aimed to investigate the regulation of PPARγ by the CMGC 
protein kinase family in more detail, and in particular to obtain mechanistic 
insight into whether the obesity induction of diabetes involved both PPARγ 
isoforms, other CMGC kinases and required the generation of p25CDK5. 
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PPARγ1  
PPARγ2 
Consensus 
 
Figure 1.4- PPARγ1 and PPARγ2 sequence alignment 
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1.8 Aims of this thesis: 
Overarching Aim: To establish the mechanism by whichCDK5,or a 
relatedCMGC kinase,links high fat and sugar diets, PPARγ and poor insulin 
action leading toT2DM. 
 
Specific Objectives: 
• To characterize and compare the phosphorylation of PPARγ isoforms by 
CMGC kinases in more detail. 
• To elucidate whether Ser273 is abnormally phosphorylated in obesity 
• To establish whether Ser273 is the only residue on PPARγ that is 
regulated by obesity 
• To investigate how p35 is converted to p25 by obesity. 
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Chapter 2- Materials and Methods 
 
2.1 Materials: 
2.1.1 Reagents 
Listed below are the most commonly used reagents bought commercially, 
prepared in the lab or obtained in house during my project.  
Commercial reagents 
Site directed mutagenesis kit and competent cells (Agilent), nuclease free water 
(Ambion), precast TGX SDS-PAGE gels 10 well and 15 well, precision plus 
protein marker, Bradford reagent, Laemmli 4x sample buffer (Biorad), 
roscovitineand purvalanolA (Cal Biotech), 10x RIPA buffer, 10x TRIS lysis 
buffer and U0126 inhibitor (Cell Signaling), enhanced chemiluminescence 
(ECL) kit (G.E. Healthcare), Fetal Bovine Serum (Gibco), penicillin/streptomycin 
(100x), trypsin/EDTA, Topo 2.1 cloning kit and competent cells, lipofectamine 
2000 reagent, plasmid mini purification kits and Simply Blue Coomassie stain 
(Invitrogen), autoradiography film and cassettes (Kodak), Dulbecco's Modified 
Eagle Medium (Life Technologies), DNA gel purification kit (Machery Nagel), 
CDK5/p35 14-477 and CDK5/p25 14-516 his tagged (Merck Millipore), 
Skimmed Milk powder (Marvel), KOD hot start polymerase chain reaction (PCR) 
kit (Novagen), DNA maxi-prep kit (Omega Biotek), [γ-
32P]adenosinetriphosphate (ATP) and  scintillation fluid (Perkin Elmer), 
nitrocellulose membrane, bicinchoninic acid (BCA) assay kit, subcellular protein 
fractionation kit (Pierce), restriction enzymes and buffers, 1kb DNA ladder, 6x 
loading dye, T4 ligase and buffer (Promega), protease inhibitor tablets (Roche), 
general laboratory chemicals, harmine, harmane inhibitor and primers for PCR 
(Sigma Aldrich), orthophosphoric Acid, DNA maxi purification kit (VWR), p81 
paper (Whatman). 
In house reagents: 
Division of Signal Transduction Therapy (DSTT) 
CDK5/p35, CDK9 his tagged, CDK7, DYRK2 GST tagged, DYRK1A GST 
tagged, DYRK 1B GST tagged, ERK2, ERK8, JNK1, JNK3, CLK2, HIPK1, 
SRPK1, GSK3β, SAPK2β, SAPK4, PCTAIRE.  
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Rat adipose tissue from standard chow and high fat fed was a kind gift from Dr 
Alison McNeilly, University of Dundee. cDNA for PPARγ1 and PPARγ2 were 
gifts from Professor Colin Palmer, CVDM, University of Dundee. TNFα was a 
gift from Dr Graham Rena, CVDM, University of Dundee 
 
Media Kitchen Services 
Liquid broth, agar, sterile water, phosphate buffered saline (PBS) 
2.1.2 Recombinant proteins 
Bacterially expressed proteins were manufactured in house by the DSTT 
pGEX-PPARγ and pGEX-PPARγ mutated constructs were provided to the 
protein production service in the DSTT. This service generated large quantities 
of purified PPARγ wild type and mutant protein fused to GST. In addition they 
produced purified PPARγ proteins lacking the GST by incubation with precision 
protease. 
2.1.3 Antibodies  
In house 
PPARγ1 and PPARγ2 were both rabbit polyclonal and were gifts from Professor 
Colin Palmer, CVDM, University of Dundee. P-Ser273 was produced in-house 
and was raised against amino acid peptides based around the Ser273 residue, 
from the 268-278 residues, of human PPARγ where the Ser273 was chemically 
phosphorylated. This peptide was injected into sheep and then subsequent 
bleeds isolated after 3 months for 3 weeks, antibodies were purified against the 
antigenic peptide by DSTT. 
Commercial primary 
Phospho-112 rabbit polyclonal (Abcam ab60953) 
Phospho-Erk rabbit monoclonal (Cell Signaling 4370) 
CDK Substrate rabbit monoclonal (Cell Signaling 9477) 
PPARγ mouse monoclonal (SCBT sc-7273), CDK5 rabbit polyclonal (SCBT sc-
173), P35 rabbit polyclonal (SCBT sc-820), FABP rabbit polyclonal (Abcam ab-
7847), actin mouse monoclonal (Sigma A8353), flag mouse monoclonal (Sigma 
F3165) 
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Commercial secondary 
Goat anti-rabbitIgG IR-dye800 (Rockland Biosciences 611-132-002), donkey 
anti-mouseIgGAlexa-Flur 350 (Invitrogen A10035), rabbit anti-sheepIgG IR-
dye800 (Rockland Biosciences 613-432-002), goat anti-rabbit 
IgGHRP(Thermo), rabbit anti-sheep IgG HRP (Thermo) 
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2.2 Methods: 
2.2.1 Buffers and solutions 
Table 2.1 includes the most commonly used buffers for my project and the 
materials they contained.  
 
Table 2.1: Table of most commonly used buffers and solutions 
Buffer Ingredients 
Lysis Buffer (Tris) 50mM Tris-HCl pH 7.4, 0.1mM EGTA, 1% (v/v) Triton 
X-100, 1mM EDTA, 1mM Na3VO4, 50mM NaF, 5mM 
Na4P2O7, 0.27M sucrose, 0.1% (v/v) β-
mercaptoethanol and protease inhibitor cocktail tablet 
Hepes Buffer 50mM HEPES, 150mM NaCl, 10% (v/v) glycerol, 1% 
(v/v) Triton X-100 pH 7.5 
NaCl buffer  50 mMTris-HCl pH 7.4, 150 mMNaCl, 0.2 mM EDTA, 
and protease inhibitor cocktail tablet 
Ripa Buffer 20 mMTris-HCl pH 7.5, 150 mMNaCl, 1 mM 
Na2EDTA, 1 mM EGTA , 1% NP-40, 1% sodium 
deoxycholate, 2.5 mMNa4P2O7, 1 mMβ –
glycerophosphate, 1 mM Na3VO4, 1 µg/ml 
leupeptinand protease inhibitor cocktail tablet 
Kinase Buffer 20mM MOPS at pH7, 1mM EDTA, 5% (v/v) glycerol , 
0.01% (v/v) Brij-35, 0.1% (v/v) β-mercaptoethanol 
and 1mg/ml BSA 
Tris-HCL buffered saline 
tween (TBST) 
50mM Tris-HCl at pH 7.5, 150mM NaCl, 0.1% (v/v) 
Tween 20 
SDS Running Buffer 250mM Tris-HCl at pH 8.3, 1.92M glycine, 1% (w/v) 
SDS 
Transfer Buffer 48mM Tris, 39mM Glycine, 20% (v/v) methanol 
TBST Blocking Buffer 50mM Tris-HCl at pH 7.5, 150mM NaCl, 0.1% (v/v) 
Tween 20 and 5% (w/v) milk 
Tris-HCl acetate EDTA 
(TAE) 
40mM Tris-HCl-acetate pH8, 100mM EDTA  
2 x BES 50mM N.N-bis(2-hydoxyethyl)-2-aminoethanesulfonic 
acid (BES), 280mM NaCl, 1.5mM NaH2PO4 at pH 
6.95 
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10 x Mg ATP 100mM magnesium chloride and 1mM ATP 
2.2.2 Molecular Biology 
2.2.2.1 Agarose gel electrophoresis 
Agarose gel electrophoresis was a technique used to separate DNA based on 
molecular size.  0.8% (w/v) agarose gels were prepared by boiling 0.4g in 50ml 
1xTAE buffer or 0.8g in 100ml 1xTAE buffer in a microwave oven. After cooling, 
2µg/ml of intercalating ethidium bromide was added. The solution was then 
poured into a gel cast with separating combs and left to set at room 
temperature. The gel was then placed into a gel-tank and submerged in 1x TAE 
buffer. The 1kb DNA ladder and the samples containing 6x DNA loading dye 
were loaded onto the gel and the gel run for 40-60minutes at 100v. The gel was 
then placed under ultraviolet light to visualise the DNA/ethidium bromide 
complexes. 
 
2.2.2.2 DNA purification from agarose gel fragments 
DNA molecules (plasmids or oligonucleotides) separated by agarose gel 
electrophoresis were cut out of the gel and the DNA purified using the 
Macherey Nagel gel extraction kit according to the manufacturer’s protocol. 
 
2.2.2.3 Polymerase chain reaction 
KOD polymerase is thermostable and possesses 3’ to 5’ exonuclease 
proofreading activity, and is used to generate PCR fragments with sticky ends. 
The standard PCR components and reaction cycles for each PCR reaction are 
listed in table 2.2 and table 2.3. The primers used for each reaction are listed in 
table 2.4. and they include the restriction sites needed for cloning, a flag tag for 
the ease of detection of PPARγ, and a Kozac sequence and ATG to initiate 
translation; these are all highlighted in bold at the start of each primer 
sequence. PPARγ2 is the product of an alternative transcription start site to 
PPARγ1, so a different 5’ primer is needed, and different restriction enzymes 
were used to clone into vectors for expression in bacteria (pGEX) or 
mammalian cells (pCMV5).  The primers to clone cDNA into pGEX contained no 
Kozac sequence or ATG as this vector introduces a 5’primed GST tag.  
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Table 2.2: Reaction Components for KOD PCR  
 
Table 2.3: Reaction cycles for KOD PCR 
 
Table 2.4: Primers used in wild type KOD PCR reactions (non-PPARγ 
sequence is shown in bold, Kozac sequence is underlined and the FLAG tag is 
in italic) 
Template  Forward/Reverse 
5-
GGTACCGCCACCATGGACTACAAGGACGACGATGACA
CCATGGTTGACAC 
PPAR γ1 -
CMV 
3-TCTAGACTAGTACAAGTCCTTGTAGATCTCCTGC 
5-
GTAGTCGACTCGACTACAAGGACGACGATGACACCATG
GTTGACAC 
PPAR γ1 -
PGEX 
3-
CAAGCGGCCGCCTAGTACAAGTCCTTGTAGATCTCCTGC 
PPAR γ2 -
CMV 
5-
GGTACCGCCACCATGGACTACAAGGACGACGATGACG
GTGAAACTCTGGG 
PPAR γ2-
PGEX 
5- 
GTCGACTCGACTACAAGGACGACGATGACGGTGAAACT
CTGGG 
 
 
2.2.2.4 Restriction enzyme digests of PCR products and plasmid DNA 
Component Volume (µl) Final 
Concentration 
10x KOD Buffer 5 1x 
25mM MgSO4 4.5 1.5mM 
dNTPs 5 0.2mM 
PCR grade water 30.5 - 
Sense (5’) Primer @ 10µM 1.5 0.3µM 
Antisense (3’) Primer @ 10µM 1.5 0.3µM 
DNA 1 0.22ng/µl 
KOD Hot Start DNA Polymerase 1 0.02U/µl 
Total Reaction Volume 50  
Step Temperature and Time 
1. Polymerase Activation 95°C for 2 minutes 
2. Denature 95°C for 20 sec 
3. Annealing 60°C for 4 cycles, 70°C for 30 more for 10sec 
4. Extension 70°C 30 sec 
5. Repeat steps 2-4 34x (changing annealing after 4) 
6. Hold 4°C 
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A standard restriction enzyme digest contained 1unit of endonuclease enzyme, 
1µl of 10x compatible buffer and 5µl of the DNA or PCR product to be digested 
with a final volume of 10µl. The solution was then incubated at 37°C for the 
amount of time specified by the manufacturers of the restriction enzyme being 
used.  
 
2.2.2.5 TOPO cloning 
The TOPO system is used to ligate DNA into the TOPO vector using 
topoisomerase I in place of DNA ligase. The topoisomerase is covalently linked 
to the vector and allows for a quick ligation. Using the TOPO system introduces 
multiple cloning sites on the vector as well as a way for the DNA to be 
sequenced easily. 4µl of PCR product was mixed with 1µl of salt solution 
(containing 0.06M MgCl2 and 1.2M NaCL) and 1µl of TOPO vector and left for 
20minutes at room temperature before transformation into TOP10 competent 
cells according to the manufacturer’s instructions.  
 
2.2.2.6 Shrimp Alkaline Phosphatase (SAP) treatment 
DNA digested with a single enzyme needs to be treated with SAP to stop the 
‘sticky’ overhanging stretch of unpaired nucleotides produced during digestion 
re-annealing with their complementary base pair and regenerating the parent 
DNA plasmid with no insert. Sticky ends occur due to the fact restriction 
enzymes digest DNA between the deoxyribose and phosphate groups, leaving 
a phosphate group of the 5’ end and hydroxyl group on the 3’ end of the DNA 
strands. SAP removes the phosphate overhang at the 5’ end to prevent self re-
ligation of linearized plasmid DNA. The plasmid DNA was incubated with 1 unit 
of SAP and SAP buffer for 37°C for 30minutes, and then the reaction stopped 
by heat inactivation of the phosphatase at 65°C for 10minutes. 
 
2.2.2.7 Bacterial transformations 
DH5α or XL1-Blue competent cells were thawed on ice and 50µl was aliquoted 
into 1.5ml eppendorf tubes. 3-5µl of DNA was added and the mixture gently 
flicked and placed on ice for 30minutes. The cells are then heat-shocked at 
42°C for 1 minute and placed on ice. Cells then had 500µl of liquid broth added 
to them and they were incubated at 37°C for 1 hour. 50µl of the transformation 
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was spread across agar plates impregnated with ampicillin (50µg/ml) and the 
plates were left overnight at 37°C to allow ampicillin resistant colonies (cells 
containing the vector) to form. 
 
2.2.2.8 Ligations 
Various vector to insert ratios (for example 7µl insert, 1µl vector, 1µl 10X buffer, 
1µl ligase) were tried for the ligation of wild type and mutant PPARγ1 and 
PPARγ2cDNA inserts into both pCMV5 and pGEX vectors. The DNA fragment 
and vector of choice were cut with compatible restriction enzymes and 
incubated together with 1 unit of T4 DNA ligase and ligase buffer in a final 
volume of 10µl, and the reaction left overnight at 4°C or at room temperature for 
3 hours. Ligation reactions were then transformed as described in section 
2.2.2.7. 
 
2.2.2.9 PCR Site Directed Mutagenesis (SDM) 
Site directed mutagenesis allows the incorporation of a base change into a DNA 
sequence to alter the amino acid in the protein sequence. The primers (shown 
in table 2.5) were designed to mutate specific Ser or Thr residues to a non-
phosphorylatable Ala. They were identical to the wild type DNA sequence of 
PPARγ, except for the desired mutation around the middle of the primer. The 
primers were designed to be 25-45 base pairs in length, with a melting 
temperature of greater than 78°C with 10-15 base pairs either side of the 
mutation. The primers did not contain more than 40% GC content which would 
increase the risk of secondary structure.  The standard reaction contained 5µl of 
10x SDM buffer, 1µl template DNA (miniprep), 1.5µl (150ng) of each primer, 1µl 
of dNTPs and 1µl of PfuUltra HF DNA polymerase (2.5 U/µl) in a final volume of 
50µl, and was placed in a themocyclerwith the reaction carried out according to 
table 2.6. Post reaction, 1µl ofDpn I restriction enzyme (10U/µl) was added and 
the reaction incubated at 37°C for 1 hour to digest parental doubled stranded 
DNA. The final product was then transformed into XL1-Blue competent cells. I 
generated the Ser273Ala mutant PPARγ, while constructs containing each of 
the other four individual phosphorylation sites for the CMGC family (proline-
directed) were generated by Dundee Cell Products. 
48 
 
 
Table 2.5: Primers used for site directed mutagenesis reactions of PPARγ1 and 
PPARγ2 
 
 
Table 2.6: Themocycler steps for mutagenesis of ser273 to alanine 
 
Template  Forward/Reverse Primer 
Sequence 
PPAR γ2 -
CMV 
5-
GACGGGTGAAACTCTGGGAGATGCTCCTATT
GACC 
ser8 
 3-
GGTCAATAGGAGCATCTCCCAGAGTTTCACC
CGTC 
ser8 
 5-
TTGACTTCTCCAGCATTTCTGCTCCACATTAC
GAAGGAC 
thr75 
 3-
GTCTTCGTAATGTGGAGCAGAAATGCTGGAG
AAGTCAA 
thr75 
 5- 
ATCAAAGTGGAGCCTGCAGCTCCACCTTATTA
TTCTG 
ser112 
 3- 
CAGAATAATAAGGTGGAGCTGCAGGCTCCAC
TTTGAT 
ser112 
 5-GACAACAGACAAGGCCCCCATTCGTTATC ser273 
 3-GATAACGAATGGGGCCTTGTCTGTTGTC ser273 
 5- 
CAAGTTCAAACACATCGCCCCCCTGCAGGAG 
thr296 
 3- 
CTCCTGCAGGGGGGCGATGTGTTTGAACTTG 
thr296 
Step Cycle Temperature and Time 
1. Polymerase 
Activation 
1  95°C for 30 seconds (initial denature) 
95°C for 30 seconds (denature) 
55°C for 1 minute (primer annealing) 
2. Denature 2-16  
68°C for 1 minute/kb of plasmid length 
(extensions) 
3. Final 
Extension 
 72°C for 7minutes 
4. Hold  4°C 
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2.2.2.10 DNA purification 
Small scale mini-preparations of DNA were produced from individual 
transformed bacterial colonies picked from agar plates. The colonies were 
transferred to 5ml of liquid broth with 50µg/ml ampicillin and grown overnight. 
The cells were pelleted by centrifugation at 4000g and DNA extracted as per 
instructions given in the Invitrogen mini-prep kit. For larger scale DNA 
preparations the transformed colonies were grown for 6hours in 5ml of liquid 
broth with 50µg/ml ampicillin, and then transferred to 200ml of liquid broth 
containing 50µg/ml ampicillin and shaken at 37°C  overnight. The DNA was 
then extracted from the pelleted cells following instructions of an Omega Biotek 
maxi-prep kit. 
 
2.2.2.11 Measurement of DNA concentration 
DNA concentration was measured by absorbance at 260nm using the nanodrop 
(Nanodrop NP8000). Absorbance readings are performed by pipetting 2µl of the 
DNA solution or dilution thereof onto the NanoDrop measurement pedestals. 
The baseline is automatically corrected at 320nm for any baseline offsets 
attributable to light scattering artifacts. 
 
2.2.2.12 DNA sequencing and analysis 
Sequencing was carried out by The Sequencing Service, Ninewells Hospital. 
Macvector software was used to align and analyse DNA sequences. 
 
2.2.3 Cell Culture 
2.2.3.1 Cell maintenance and passage 
Human embryonic kidney cells (HEK-293), HeLa cells and 3T3-L1 cells were 
cultured in Dulbecco’s modified Eagle’s medium high glucose (DMEM) with 
10% fetal bovine serum (FBS) and 5% penicillin streptomycin and split when 
confluent with trypsin, phosphate buffered saline (PBS) and media pre-warmed 
to 37°C before use. The Flp-In T-Rex-293 cells were grown and treated as 
described in section 2.2.4.3 
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2.2.3.2 3T3-L1 Cell Differentiation 
Cells were split into 6 well plates. Once confluent (day 0) the cells were placed 
in fresh basal medium for 2 more days (day 2) and then incubated with insulin 
(167nΜ), IBMX (0.115mg/ml) and dexamethasone (10µM) for a further 2 days. 
Finally the cells were incubated in insulin (167n for 2-3 days prior to placing in 
basal medium again for a further 2 days. The media was removed and cells 
either stained for lipid (Oil Red O) or lysed for measuring protein concentration 
and identification of proteins of interest by western blotting. 
 
2.2.4 DNA Transfections 
 
2.2.4.1 Calcium-phosphate DNA precipitation inBES buffer 
 
Table 2.7:BES transfection protocol method 
 
Plate/dish 6 well plate 6cm dish 10cm dish 
2x BES 150 µl 200  µl 250 µl 
Nuclease free water up to 135µl up to 177.5µl up to 220 µl 
DNA 1 µg 2 µg 3 µg 
2.5M CaCl2 15 µl 22.5 µl 30 µl 
Volume per dish/well 300 µl 400 µl 500 µl 
 
Nuclease free water and 2x BES buffer were combined in a 14 ml 
polypropylene tube as described in table 2.7 and gently flicked. The DNA to be 
transfected was then added to the tube with the tube being gently flicked during 
addition. Fresh CaCl2 was added according to the volume in table 2.7 drop-wise 
and the tube left at room temperature for 20minutes, with gentlemixing every 2-
3 minutes to allow an even precipitate to form. The precipitate was then pipetted 
drop-wise all over the cellswhich were thenincubated at 37°C with 5% CO2. 
After 4 hours fresh media was added to the cells and the plates left in the 
incubator for 12-20hrs.  
 
2.2.4.2 Lipofectamine 
DNA was introduced into cells using Lipofectamine 2000 (Invitrogen) as per 
manufacturer’s instructions. Briefly, the DNA and lipofectamine solution were 
mixed together with basal media before adding this mixture to the cells. For 6 
wells plates, 4µg DNA in 150µl DMEM and 6µllipofectamine in 150ml DMEM 
were combined and left for 10 minutes at room temperature whilst antibiotic free 
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media was added to the cells. The solution was then added to the cells and left 
for 4 hours at 37°C, prior to addition of growth media and incubation at 37°C for 
12-20hrs. 
 
2.2.4.3 Production of a cell line with inducible PPARγ expression (FT-PPARγ) 
The Flp-In T-Rex-293 cell line can be used as a host to generate a tetracycline-
inducible Flp-In T-Rex expression cell line by co-transfecting the FRT 
expression vector containing PPARγ(FRT-PPARγ), and the Flprecombinase 
expression plasmid, pOG44 (O’Gorman et al., 1991). The pOG44 mediates 
integration of the FRT vectorcontaining PPARγ into the genome via Flp 
Recombination Target (FRT) sites. Flp-In T-Rex 293 cells are grown in zeocin 
selection media (DMEM + 10% FBS + 5% penicillin streptomycin + 100µg/ml 
zeocin + 15µg/ml blasticidin) and then plated in complete media (DMEM high 
glucose + 10% FBS + 5% penicillin streptomycin). Zeocin is used as a selective 
agent forthe FRT-PPARγ plasmid and blastacidin is used as a selection agent 
for the pOG44 plasmid. FT-PPARγ was transfected into the cells with pOG44 at 
a 1:5 ratio in serum free media with lipofectamine and grown in complete media 
overnight. Cells were passaged and media changed to HSM media (DMEM 
high glucose + 10% FBS + 5% penicillin streptomycin + 75µg/ml hygromycin + 
15µg/ml blastacidin).Following co-transfection, the Flp-In T-Rex-293 expression 
clones become sensitive to zeocin,therefore the selection medium cannot 
contain zeocin, and instead the stable transfectants are selected using 
hygromycin B. The medium should still contain blasticidin for selection for the 
pOG44 plasmid. 24 hours before harvest, cells were treated with 1µg/ml 
tetracyclineto induce PPARγ expression. 
 
2.2.4.4 Treatment of cells with inhibitors and stimulants 
To try to induce and to inhibit PPARγ phosphorylation in cells, various 
stimulants and inhibitors were tried.  Media was removed and the cells were 
incubated for 3-12hrs in pre-warmed serum free DMEM containing 
penicillin/streptomycin to serum-starve cells. Inhibitors and stimulants were 
added at the concentrations and for the times stated in the figure legends prior 
to cell lysis and immunoblot to measure protein phosphorylation. 
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2.2.5 Protein Isolation and Purification 
2.2.5.1 Lysis of cells 
To harvest protein from the cells the plates were placed on ice and the media 
aspirated prior to wash with ice-cold PBS.  Between 200µl and 1ml of freshly 
prepared ice-cold lysis buffer (either TRIS or RIPA, see Table 2.1) was added 
(depending on number of cells being harvested) and left for 5 minutes on ice. 
Cells were then scraped into pre-chilled eppendorf tubes, pippetted up and 
down and spun at 13,000g at 4°C for 10 minutes. The supernatant contained 
cellular protein; this was measured by the method of Bradford or BCA (see 
later), was snap frozen on liquid nitrogen and kept at -20°C until required. 
 
2.2.5.2 Lysis of tissues –lysis buffer 
Rat adipose tissue was weighed out under liquid nitrogen. The frozen tissue 
was ground with a pestle and mortar under liquid nitrogen prior to addition of an 
equal volume of lysis buffer (TRIS, RIPA - see Table 2.1) and pippetting up and 
down. Alternatively, tissue was homogenized in HEPES buffer, with a hand held 
douncehomogeniser on ice instead of pestle and mortar. The samples were 
further homogenized using a sonicator for 10 minutes, and then spun at 13000g 
at 4°C for 30 minutes. The fat layer was removed and the protein containing 
supernatant was placed in a fresh eppendorf tube and spun for a further 10 
minutes and any remaining lipid layer removed. Protein was measured in the 
samples, they were snap frozen on liquid nitrogen, and placed in a -20°C 
freezer until required. 
 
2.2.5.3 Lysis of tissues – solvent extraction 
Rat adipose tissue was weighed out under liquid nitrogen.  The tissue was 
pulverized under liquid nitrogen using a 2:1 solution of chloroform and methanol 
in a pestle and mortar. The lysate was then placed into a 15ml falcon tube and 
left on ice for 15minutes. A 1:1 ratio of chloroform:water was added  to the 
lysate and solution mixed. The lysate was then spun at 800g for 5minutes at 
4°C and both upper aqueous phase and protein disc collected in eppendorf 
tubes. 3 volumes of 10% TCA in water was added to each tube and left 
overnight at 4°C to precipitate protein. The pellets were then washed in acetone 
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to remove the TCA and left to air dry before the addition of SDS containing 
sample buffer for analysis by immunoblot. 
 
2.2.5.4 GST Purification of pGEX PPARγ 
The pGEX-PPARγ and pGEX-PPARγ mutant constructs were provided to the 
protein production service in the DSTT, CLS. This service generated large 
quantities of purified PPARγwild type and mutant protein fused to GST. In 
addition they produced purified PPARγ proteins lacking the GST by incubation 
with precision protease. 
 
2.2.5.5 Protein immunoprecipitation 
Antibodies that are raised against an endogenous target protein or a 
recombinant tag can be coupled to protein G sepharose or agarose beads; this 
is then used to isolate the protein of interest from cell or tissue lysates. Protein 
G Beads were washed in 500µlPBS and spun in a centrifuge at 2000g twice to 
remove ethanol. After the second spin, beads were left in a 50/50 slurry of 
PBS/beads. The antibody of choice was then added to the 50/50 slurry of beads 
(1µg antibody per 10µl beads) and incubated shaking for 1 hour at room 
temperature. The beads were then washed with PBS at 2000g twice. 100-
500µg of sample was added to 20µl of 50/50 antibody beads and left overnight 
at 4°C shaking. The following day the solution was spun to pellet the beads-
antibody and any associated protein and then washed with lysis buffer twice. 
40µl of 1x SDS sample buffer was added to the beads and heated at 70°C for 
10minutes to release protein into the sample buffer. The samples were then 
centrifuged at 13000g for 1 minute and the supernatant kept at -20°C. 
 
2.2.5.6 Covalent linkage of antibodies 
Antibody-coupled beads were prepared as described in section 2.2.5.5. The 
beads were then washed and spun in 500µl pH9 0.1M sodium borate twice. The 
beads were then re-suspended in 500µl fresh 20mM DMP in 0.1M sodium 
borate and shaken for 30minutes at room temperature. The tubes were then 
spun at 2000g and supernatant removed. The beads were re-suspended in 
500µl 20mM DMP in 0.1M sodium borate and shaken for a further 30minutes at 
room temperature. The beads were then washed at 2000g twice with 500µl 
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pH2.5 50mM glycine. The beads were then washed 3x with PBS and once with 
500µl lysis buffer, before re-suspension as a 50/50 slurry in lysis buffer; these 
beads were then used to immunoprecipitate proteins as described in section 
2.2.5.5. 
 
2.2.5.7 Measuring protein concentration using Bradford 
Protein concentrations were measured using the Bradford method (Bradford, 
1976), or using bicinchoninic acid (BCA) assay (see section 2.2.5.7). The 
Coomassie G-250 dye in the Bradford reagent binds to protein inan acidic 
environment, resulting in a spectral shift from red 465nm to blue 595nm. The 
more protein there is present, the darker blue the colour. A calibration curve 
covering 0-5mg/ml bovine serum albumin (BSA) standard was performed in 
triplicate in a 96well plate. Samples of unknown protein concentration were 
added to the plate in 200µl of Bradford reagent. After incubation at room 
temperature for 10minutes the absorbance at 595nm was obtained and a 
standard curve plotted (Fig 2.1). 
Figure  2.1 - An example of a standard curve from a Bradford assay used to measure protein 
concentration in mg/ml 
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2.2.5.8 Measuring protein concentration using BCA 
A BCA assay was needed to measure protein concentration when RIPA lysis 
buffer was used; this is due to incompatibility ofthe Bradford assay with the 
sodium dodecyl-sulphate (SDS) present in RIPA buffer. The BCA assay 
consists of 2 reactions. Firstly peptide bonds in any protein present in a sample 
cause Cu2+in the BCA reagent to be reduced to Cu+. Secondly, two molecules 
of BCAchelate with each Cu+ion to form a purple product that absorb at 562nm. 
As with the Bradford assay a calibration curve of 0-2mg/ml BCA was performed 
along with the samples of interest. 200µl of the working reagent provided was 
added to each standard and sample and incubated at 37°C for 30minutes. The 
plate was cooled and then absorbance values read on a spectrophotometer at 
562nm.  
 
 
2.2.6 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is a technique used to separate proteins according to their 
molecular weight using an electrical current (Laemmli 1970).  SDS or lithium 
dodecyl-sulphate (LDS) sample buffer is added to the samples to denature any 
protein present and to coat them with a negative charge in a uniform mass to 
charge ratio. The SDS buffer added to the sample also contains DTT to reduced 
disulphide bonds between cysteine residues, in addition to the negatively 
charged sulphate groups disrupting the hydrophobic amino acid interactions. 
After the addition of the sample buffer the samples are heated at 70-95°C for 10 
minutes for further denaturing of the proteins before being loaded onto a pre-
cast 4-15% Biorad gel. A molecular weight marker was also loaded onto the gel 
for use as an internal standard curve. The gels were then run at 120-160V with 
1x SDS running buffer, with the negative charge causing the sample to move 
towards the positively charged electrode. Smaller proteins travel further down 
the gel due to their ability to diffuse through the gel pores faster. 
 
2.2.7 Coomassie staining 
Proteins present on the SDS-PAGE gels were visualised using Coomassie 
staining, unless they were to be transferred to nitrocellulose for western blotting 
(section 2.2.8). The gel was washed 3 times for 5 minutes with deionized water 
on a shaking platform; and then immersed in Simply Blue stain for 1 hour at 
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room temperature. The gel was then de-stained with water on a shaker for 1 
hour at room temperature, or overnight if a more thorough de-stain was 
required. The coomassie dye binds to protein in the acidic environment allowing 
them to be visualised under visible light. 
2.2.8 Western Blots  
2.2.8.1 Transfer of proteins onto a nitrocellulose membrane 
To transfer protein samples from the gel to a 0.45mm nitrocellulose membrane 
(Hybond C-Extra, GE Healthcare), after SDS-Page, the gel and membrane are 
pre-soaked in transfer buffer and a current of 35V applied for 2 hours to allow 
the negatively charged proteins to transfer from the gel to the membrane by 
moving towards the positive cathode. 
 
2.2.8.2 Immunoblotting 
Immunoblotting allows the visualization of specific proteins of interest via 
interaction with specific antibodies. Firstly the nitrocellulose membrane 
containing the transferred proteins from the SDS-PAGE above was blocked for 
1 hour at room temperature in TBST blocking buffer to prevent any non-specific 
binding of the primary antibodies to the membrane. The blocked membrane was 
then incubated overnight at 4°C with the primary antibody of choice (diluted in 
the blocking agent) on a rolling mixer. The following day the membranes were 
rinsed 3 times for 10 minutes in TBST at room temperature, to remove any 
unbound antibody. The membrane was then incubated for 1 hour at room 
temperature on a shaker with the secondary antibody of interest (diluted in the 
blocking agent), before being washed 3 times for 10 minutes in TBST to remove 
any unbound secondary antibody. The membrane was then left in TBST 
covered at 4°C until visualisation. 
 
2.2.8.3 Visualisation 
Membranes were either visualised using the Licor Odyssey infrared detection 
system, or by chemilluminesence (ECL). If the secondary antibody is 
conjugated with horse radish peroxidase then this enzyme will generate 
chemiluminescent light when incubated with luminol (ECL reagent), and this can 
be detected on photographic film.  Alternatively, if the secondary antibody is 
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conjugated to infrared emitting dyes the light emission can be detected directly 
using the Licor Odyssey scanner. 
2.2.9 Preliminary Characterisation of Phosphospecific Antibody  
Peptides (0.5-10ng) based around the PPARγ sequence surrounding Ser273, 
one with the Ser273 chemically phosphorylated were dotted onto nitrocellulose 
membranes. The membranes were blocked in 5% milk in TBST and incubated 
overnight with the phospho-specific Ser273 antibody at dilutions of 1 in 200 or 1 
in 1000, followed by secondary antibody linked to HRP (Fig 2.2). The blots were 
then developed by ECL as described in section 2.2.8.3. 
 
 
 
2.2.10 Kinase Assays 
2.2.10.1 Myelin Basic Protein Assay 
To measure the specific activity of a kinase before use in an in-vitro kinase 
assay, it was measured against myelin basic protein activity by incubation at 
30°C with Mg[γ-32P]ATP for 10 minutes. The kinase reaction was stopped after 
10 minutes by adsorption of 40µl (50µl total assay volume) onto squares of 
phospho-cellulose p81 paper, followed by dropping the squares immediately 
into 75mM phosphoric acid. The squares were then washed 3x in the 
phosphoric acid to remove any unincorporated Mg[γ-32P]ATP.  A final wash in 
acetone dried the squares before they were placed in a scintillation vial for 
counting as described in section 2.2.10.2 
 
2.2.10.2 In-vitro kinase assay 
Active CDK5/p25 and active CDK5/p35 were purchased from Milllipore. GST 
and cleaved wild type and Ser273Ala PPARγ1 and PPARγ2(5µM) were 
incubated (60µl assay) with each CDK5 complex plus Mg[γ-32P]ATP (10mM 
Figure 2.2 - Dot blot characterising p-Ser273 antibody using a) phosphopetide to ser273 and b) 
dephospho peptide to ser273 
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MgCl2, 0.1mM ATP, approx 0.5 x 106 CPM/nmole) or non-radioactive MgATP, 
in kinase assay buffer (20 mM Mops, 1mM EDTA, 5% glycerol, 0.01% Brij-35, 
0.1% β-mercaptoethanol, and 1mg/ml BSA). After10, 30, 60 and 180 minutes at 
30°C equal aliquots of the sample were taken and the reaction stopped with 
appropriate amounts of 4x SDS sample buffer and heating for 10 minutes at 
95°C. CDK5 was added at the activity indicated in the figure legends. When 
other CMGC kinases were used, the specific activities were matched using 
myelin basic protein (MBP) as a common substrate and an equal amount of 
units of MBP kinase activity used in the assay but in a 30µl assay volume for 30 
minutes. The [Ser8Ala]PPARγ, [Thr75Ala]PPARγ, [Ser112Ala]PPARγ, and 
[Thr296Ala]PPARγ proteins were all incubated with the CMGC kinases at 5µM. 
 
2.2.10.3 Phosphorylation measurements 
The reactions from above were loaded on a precast Biorad 4-12% SDS-PAGE 
system to separate the phosphorylated substrate from other assay constituents. 
Gels were Coomassie stained, dried and visualised by autoradiography and 
phospho-image analysis. Phosphorylation was quantified by carefully cutting gel 
pieces containing the stained PPARγ and counting in 2ml of scintillation fluid. 
The number of nanomoles of ATP transferred into protein was calculated from 
the specific activity of the ATP used in the reaction and this was used to 
establish the mole per mole incorporation or the specific activity of the kinase 
toward the substrate. One unit of activity is defined as 1 nanomole of phosphate 
incorporated into substrate per minute. The [Ser8Ala]PPARγ, [Thr75Ala]PPARγ, 
[Ser112Ala]PPARγ, and [Thr296Ala]PPARγ mutant proteins were analysed for 
degradation by SDS-PAGE and Coomassie staining. Densitometry was used to 
correct for variations in degradation between the mutant proteins. Briefly, 2µg of 
each protein was loaded onto a precast Biorad 4-12% SDS-PAGE system in 
duplicate, and the gels Coomassie stained and scanned on the Odyssey 
system. The CB signal ratios of the upper (full length protein) to lower bands 
(degradation products), total signals and ratios relative to the wild type PPARγ 
were calculated, and counts normalized to the wild type; this was repeated to 
get an average result for the normalization across three separate gels. 
 
2.2.11 Statistics 
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The statistics throughout this thesis were based on the range, rather than 
standard deviation and the coefficient of variance,due to the availability and 
stability of the CMGC kinases. The error bars were based on a range of n=2.  
Chapter 3 -In vitro Assessment of PPARγPhosphorylation 
 
3.1 Introduction 
 
Previous work implicated the phosphorylation of PPARγ at Ser273 by CDK5 as 
a molecular link between obesity and diabetes, as well as the response to 
glitazone therapy (Choi et al). However this work raised multiple questions 
including how obesity regulated CDK5, and indeed why CDK5 would 
phosphorylate Ser273, which did not fit a consensus sequence for this 
kinase.Others have shown that additional CMGC kinases can phosphorylate 
PPARγ (Camp and Tafuri 1997); albeitthese are likely to phosphorylate PPARγ 
at ser112 (Adams et al 1997).  
 
In order to fully establish whether PPARγ was truly a target for CDK5 or a 
related kinase in this Chapter I have performed a series of in vitro experiment to 
address the following aims: 
 
• To establish whether CDK5 phosphorylates PPARγin vitro  
• To identify the residues phosphorylated by CDK5 
• To compare the rates of PPARγ phosphorylation between each CDK5 
complex 
• To compare PPARγisoforms phosphorylation  
• To establish whether other CMGC kinases phosphorylate PPARγin vitro 
and if so at what residues 
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3.2 Results 
3.2.1.CDK5 phosphorylation of wild type PPARγ1 and PPARγ2 
To investigate the potential for PPARγ to act as a substrate for CDK5 
complexes in vitro I measured phosphate incorporation into bacterially 
expressed PPARγ1 when it was incubated with either CDK5/p35 or CDK5/p25 
(after activities were matched against histone) and [γ-32P]-ATP. CDK5/p35 
phosphorylated a GST-PPARγ1 fusion protein faster and to greater extent than 
CDK5/p25 (Fig 3.1). In order to ensure that this difference was not due to the 
presence of the GST I repeated the experiment using a PPARγ1 protein after 
the GST was removed by proteolytic cleavage. Once more CDK5/p35 
phosphorylated PPARγ1 faster and to greater extent than CDK5/p25 (Fig 3.1).  
Phosphorylation reached around 0.1 to 0.2 mole/mole within 10 to 30 minutes, 
and the GST tag did not seem to alter overall phosphorylation. 
 
Next I compared phosphorylation of GST-PPARγ1 to that of GST-PPARγ2 with 
both CDK5 complexes (Fig 3.2). CDK5 phosphorylated each GST-PPARγ to a 
similar extent (0.1 to 0.2 mol/mol within 30 mins) and as with PPARγ1 
CDK5/p35 phosphorylated GST-PPARγ2 to a greater extent than CDK5/p25 
(Fig 3.2).  
 
Figure 3.1:In vitro phosphorylation of PPARγ by CDK5 complexes (1006mU,  n=2). WT; wild 
type PPARγ, 35; CDK5/p35 complex, 25; CDK5/p25 complex, error bars represent the range. 
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Figure 3.2:In vitro phosphorylation ofGST PPARγ1 and PPARγ2 by CDK5 complexes for 30 
minutes (1006mU, n=2) p35; CDK5/p35 complex, p25; CDK5/p25 complex, error bars represent 
the range 
 
 
3.2.2 Investigation into CDK5 phosphorylation of Ser273 
 
Next I investigated how much of the phosphate incorporated into PPARγ by 
CDK5 was going into Ser273. I compared the phosphorylation of wild type 
PPARγ1 to that of the [Ser273Ala]PPARγ1 mutant, by both CDK5/p35 and 
CDK5/p25, for both GST and cleaved PPARγ1; to confirm the mutation was 
present, the mutated protein was sequenced and compared to the wild type.  
Once more CDK5/p35 phosphorylated PPARγ1 to a greater extent than 
CDK5/p25 (Fig 3.3, Fig 3.4). There was no greatdifference in phosphorylation of 
GST-PPARγ1 and GST-[Ser273Ala] PPARγ1 by either CDK5 (Fig 3.3 and Fig 
3.4). CDK5/p35 phosphorylation of the GST-[Ser273Ala] PPARγ1 was lower 
than that of GST-PPARγ1, but the decrease did not show a statistical trend. In 
addition phosphorylation of PPARγ1 wild type and [Ser273Ala]PPARγ1 lacking 
the GST tags (cleaved) was identical with both CDK5/p25 and CDK5/p35 (Fig 
3.4). The fact mutation of Ser273 to an alanine has no great effect on 
phosphorylation of the PPARγ1 suggests this is not a target for CDK5, at least 
in vitro.
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Figure 3.3: In vitro phosphorylation of GST-PPARγ1 wild type and [Ser273Ala] PPARγ1 mutant 
by CDK5 complexes (1006mU, n=2) WT; wild type, Mut; Ser273Ala, p35; CDK5/p35 complex, 
p25; CDK5/p25 complex, error bars represent the range 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: In vitro phosphorylation of cleaved PPARγ1 wild type and [Ser273Ala] PPARγ1 
mutant by CDK5 complexes (1006mU,  n=2). WT; wild type, Mut; Ser273Ala, 35; CDK5/p35 
complex, 25; CDK5/p25 complex, error bars represent the range 
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To further confirm this I incubated FLAG-tagged PPARγ1 and PPARγ2 with 
non-radioactive ATP and either CDK5/p25, CDK5/p35, or ERK2. ERK2 is 
reported to phosphorylate PPARγ at Ser112 (Adams et al 1997). These 
incubations were probed by immunoblot using antibodies to FLAG (for loading), 
phospho-Ser122 and phospho-Ser273. As expected, incubation with ERK2 
induced phosphorylation of Ser112 in both PPARγ isoforms (Fig 3.5).  
Incubation of PPARγ1 and PPARγ2 with either CDK5/p25 or CDK5/p35 did not 
increase phosphorylation of either Ser112 or Ser273, providing further evidence 
that CDK5 does not phosphorylate PPARγ at Ser273 and that the phosphate 
incorporation by CDK5 is also unlikely to occur at Ser112. Similarly ERK2 does 
not phosphorylate Ser273 of PPARγ (Fig 3.5). The caveat to this experiment is 
that we have not yet obtained a positive control of phosphoSer273 PPARγ to 
validate the phospho specific antibody. The antibody has, however, been tested 
with phospho and non phospho peptide incubations as shown in the dot blots 
(fig 2.2); any signal picked up might be non-specific background due to the lack 
of positive control. 
 
Figure 3.5: Immunoblot of GST-Flag-PPARγ1 and PPARγ2, following incubation with 
CDK5/p35, CDK5/p25 or ERK2 using antibodies as indicated (MW ~80KD). Control is PPARγ1 
or PPARγ2 alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Anti-pSer273 
Anti-pSer112 
Anti-FLAG (load) 
 
PPARγ2 
p35 p25 ERK  con 
PPARγ1 
p35 p25 ERK  con 
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3.2.3 Phosphorylation of PPARγ2 by other CMGC kinases 
 
Although my data above indicated that CDK5 did not phosphorylate Ser273 of 
PPARγ it remained possible that the reported regulation of this site was actually 
by a related kinase. Therefore I investigated whether other GMGC kinases 
could phosphorylate GST-PPARγ2 and GST-[Ser273Ala]PPARγ2in vitro. 
PPARγ2 was chosen for the kinase screen as it contains all of the proline 
directed sites (potential targets of this family of kinases) present in PPARγ1, 
plus an additional site within the N-terminal extension. This allowed me to 
investigate whether any of the CMGC kinases phosphorylated any of the 5 
potential proline-directed residues in PPARγ (see Fig 1.3). I was able to source 
a range of CMGC family members, and tried to include at least one from each 
major subgroup of the CMGC kinases (unfortunately the SRK group were not 
available). Of the 17 kinases investigated (Fig 3.6) eight phosphorylated 
PPARγ2, namely ERK2, ERK8, DYRK1A, DYRK1B, DYRK2, SAPK4, CDK9 
and CDK5. However all of the kinases phosphorylated [Ser273Ala]PPARγ2 to a 
similar extent to the wild type PPARγ2 (Fig 3.6).  It should be noted that for 
some of the kinases the inherent autophosphorylation meant that accurate 
assessment of PPARγ2 phosphorylation was difficult; for example compare – 
lanes with + lanes for DYRK2, ERK2 and ERK8 (Fig 3.7). In all cases the 
radioactivity in the – lane (in the PPARγ2 gel piece) was subtracted from the + 
lane to account for background due to autophosphorylation of the kinase. 
 
Each of the CMGC kinases that radiolabelledPPARγ2was then incubated with 
GST-Flag-PPARγ2 and non radioactive MgATP, followed by western blot with 
PPARγ, CDK substrate, p-Ser273and p-Ser112 antibodies; in order to examine 
whether any of the kinases phosphorylate either of these residues, while anti-
PPARγwas used as the loading control. The results confirmed that ERK2 
phosphorylates PPARγat Ser112, while DYRK2 and SAPK4 also 
phosphorylated Ser112 (Fig 3.8). ERK8, DYRK1A, DYRK1B and CDK9 did not 
phosphorylate PPARγ at Ser112 (Fig 3.8). None of the kinases appeared to 
induce phosphorylation at Ser273 to a great amount, at least as detected by this 
phosphospecific antibody. In addition, PPARγ incubated with ERK2 or the 
DYRKs was detected weakly by the cdk-substrate antibody(Fig 3.8), but as it 
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did not detect PPARγ incubated with SAPK4 it seems unlikely this antibody 
detects Ser112 phosphorylation. 
Figure 3.6: CMGC Kinase Screen with activity matched to myelin basic protein and incubated 
with PPARγ2 wild type and [Ser273Ala]PPARγ2(x, n=2) 
 
Figure 3.7: Autoradiograph showing examples of the data used to generate Fig 3.6. 
Incubationswere Mg[32P]ATP plus kinase alone (-) orkinase + PPARγ2 (+) as indicated. 
 PPARγ2-     +    +    -     +   +    -     +     + 
          DYRK1A               DYRK1B       SAPK4  
PPARγ2-    +     -   +    -   +    -   +       -   + 
DYRK2    CDK9   ERK2      ERK8     JNK1     
PPARγ2 
PPARγ2 
PPARγ2 
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Figure 3.8: CMGC kinases that phosphorylatedPPARγ2were incubated with non radioactive 
MgATP and GST-Flag-PPARγ2 followed by western blot with PPARγ, CDK substrate, p-Ser273  
and p-Ser112 antibodies as indicated (MW ~80KD). Control is PPARγ2 alone and band 
intensity is compared with control to see any increase in phosphorylation 
 
 
Control      DYRK2 DYRK1A  DYRK1B  ERK2    ERK8     CDK9    SAPK4  
Anti-PPARγ  
 
 
 
 
Anti-pS112 
 
 
 
 
 
 
Anti-CDK Substrate 
 
 
 
 
 
Anti-pS273 
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3.2.4 Proline Directed Phosphorylation of PPARγ2 
 
There are five sequences within human PPARγ that conform to a minimum 
consensus for the CMGC family of protein kinases, namely a Ser or Thr residue 
immediately followed by a Pro (Fig 1.3). These lie at Ser8, Thr75, Ser112, 
Thr296 and Ser273. We generated PPARγ2 mutants with each of these five 
Ser/Thr residues changed to a non-phosphorylatableAla residue and incubated 
them (only [Ser8Ala]PPARγ, [Thr75Ala]PPARγ, [Ser112Ala]PPARγ, and 
[Thr296Ala]PPARγ as Ser273Ala PPARγ was investigated earlier),with the 
CMGC kinases from section 3.2.3.  
 
Unfortunately, there was variable degradation of the recombinant proteins 
during the purification process, (as visualised by Coomassie stain, Fig 3.9) thus 
I had to perform a normalisation to correct for the presence of different amounts 
of full length protein in each sample (Fig 3.9 and Table 3.1). The degradation 
was calculated by looking at the averages of the signals of PPARγfrom the 
Odyssey, the total signal of the upper (full length PPARγ) and lower (degraded 
PPARγ) bands, the ratio of the upper bands to lower bands and the ration of 1 
to the upper band.The [Thr75Ala]PPARγ mutant protein in particular had 
relatively low levels of full length protein thus data with this mutant is treated 
with caution. The degradation was easily accounted for on the autorads, as the 
PPARγ2bands seen further down the Coomassie stain with lower molecular 
weights than full length PPARγ2, were also visible on the autorad after 
incubation with the various CMGC kinases. 
 
After correction for relative amount of full length PPARγ2 there was no 
indication that phosphorylation of any mutant varied from that of wild-type 
following incubation with CDK5/p35 (Fig 3.10A). There is less radioactivity 
incorporated into the [Thr75Ala]PPARγ, [Ser112Ala]PPARγ, and 
[Thr296Ala]PPARγ mutants compared with wild type PPARγ2 (Fig 3.10B), 
however after accounting for the variability in degradation of the substrates 
there was no evidence that these mutations significantly prevented 
phosphorylation (mole/mole). It is possible that further investigation of Thr296 is 
merited as in one of the two experiments (Fig 3.10B) there appeared to be 
lower phosphorylation (levels of full length Thr296Ala are similar to Ser8Ala, 
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compare phosphate incorporation of these two mutants), but this was not seen 
in the second experiment. Similarly the only PPARγ2 mutant that appeared 
poorly phosphorylated by CDK9, was [Thr296Ala]PPARγ (compared to wild 
type and Ser8Ala phosphorylation, Fig 3.11A and B). 
 
Mutation of Ser112 of PPARγ2 to an Alagreatly reducedphosphorylation by 
ERK2 (Fig 3.12A and B) consistent with the data in section 3.2 and published 
data (Adams et al 1997) indicating that ERK2 phosphorylates PPARγ at 
Ser112. However the phosphorylation of PPARγ was not completely depleted 
by this mutation, suggesting some phosphorylation of alternative site(s) and 
combinatorial mutations would be required to assess this.  
 
Phosphorylation by ERK8 is relatively weak compared to the other kinases 
studied here, making it very difficult to interpret the result of the point mutations 
(Fig 3.13A and B). The molecular weight of the ERK8 used was relatively close 
to that of PPARγ2, as is seen on the autorad in figure 3.13B, so the ERK8 might 
be interfering with PPARγ2 bands analysed.The Ser112Ala mutation appeared 
to reduce phosphorylation in one experiment but this was not seen consistently 
and earlier data using immunoblot had indicated this is unlikely to be a major 
target for ERK8 (Fig 3.8). 
 
Confusingly, phosphorylation of both [Ser112Ala]PPARγand 
[Thr296Ala]PPARγby SAPK4 was reduced compared to the wild type (Fig 
3.14A and B); this could be dues to issues with the degradation of the mutated 
PPARγ2.  The immunoblot work from section 3.1.3 also suggested SAPK4 
could phosphorylate Ser112, thus this seems to be a likely target for SAPK4. 
However it remains feasible that SAPK4 may also phosphorylate Thr296, or this 
region is involved in the interaction with SAPK4. 
 
Auto-phosphorylation of DYRK2 resulted in high background radioactivity in the 
region of the gels used to assess the phosphorylation of PPARγ2 (Fig 
3.15).Another issue with DYRK is that it lies very closely in molecular weight to 
PPARγ2, making it hard to distinguish from PPARγ2 on an autorad. To try to 
solve the auto-phosphorylation problem, I pre-incubated DYRK2 with non-
radioactive ATP for 30minutes in an attempt to induce non-radioactive auto-
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phosphorylation and thus decrease background radioactivity in these 
incubations. Subsequent phosphorylation of the [Ser112Ala]PPARγby DYRK2 
appeared lower than wild type protein (Fig 3.16A and B), again agreeing with 
the immunoblot data in section 3.1.2. In contrast DYRK1B seemed to 
phosphorylate all of the PPARγ2 mutants, making it hard to establish which site 
may be targeted by these kinases (Fig 3.17A and B), and combinations of 
mutants may be needed to fully characterize this phosphorylation. DYRK1A 
incubation with the PPARγ2 mutants proved hard to get consistent results due 
to the high level of auto-phosphorylation, so the data is not included. 
70 
 
 
Figure 3.9: Coomassiestained SDS-PAGE gelof the GST-PPARγ2 mutants (upper gel), with 
lower gel showing areas quantified to generate the normalization ratios in Table 3.1.  
WTPPARγ2Ser8AlaThr75AlaSer112AlaThr296Ala 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1: Normalization ratios to account for variable degradation of the GST-PPARγ2 
mutants 
 
 
 
 
 
 
 
 
Protein Normalisation for degradation 
Wild Type PPARγ2 1 
S8A PPARγ2 2.8 
T75A PPARγ2 11.1 
S112A PPARγ2 5.3 
T296A PPARγ2 3.5 
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Figure 3.10: (A) Graphical representation ofmol/mol stoichiometry of PPARγ2 mutants byCDK5 
and (B) arepresentative autoradiograph of phosphorylation of PPARγ2 mutants, including 
control CDK5 alone lane (no PPARγ2 present) 
 
A 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PPARγ2 
 
 
 
 
 CDK5 
CDK5WTPPARγ2Ser8AlaThr75AlaSer112AlaThr296Ala  
alone 
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Figure 3.11: Graph (A) representing mol/mol stoichiometry of the phosphorylation of PPARγ2 
mutants byCDK9 and autorad (B) showing phosphorylation of PPARγ2 mutants, including 
control CDK9 alone lane (no PPARγ2 present) 
 
A 
 
B 
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Figure 3.12: Graph (A) representing mol/mol stoichiometry of the phosphorylation of PPARγ2 
mutants byERK2 and autorad (B) showing phosphorylation of PPARγ2 mutants, including 
control ERK2 alone lane (no PPARγ2 present) 
 
A 
 
B 
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Figure 3.13: Graph (A) representing mol/mol stoichiometry of the phosphorylation of PPARγ2 
mutants byERK8 and autorad (B) showing phosphorylation of PPARγ2 mutants, including 
control ERK8 alone lane (no PPARγ2 present) 
 
A 
 
B
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Figure 3.14: Graph (A) representing mol/mol stoichiometry of the phosphorylation of PPARγ2 
mutants bySAPK4 and autorad (B) showing phosphorylation of PPARγ2 mutants, including 
control SAPK4 alone lane (no PPARγ2 present) 
 
A 
 
B 
PPARγ2 
 
 
 SAPK4 
SAPK4 aloneWTPPARγ2 Ser8AlaThr75AlaSer112AlaThr296Ala 
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Figure 3.15: Graph (A) representing mol/mol stoichiometry of the phosphorylation of PPARγ2 
mutants byDYRK2 without pre-incubation and autorad (B) showing phosphorylation of PPARγ2 
mutants,including control DYRK2 alone lane (no PPARγ2 present) 
 
A 
 
B 
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Figure 3.16: Graph (A) representing mol/mol stoichiometry of the phosphorylation of PPARγ2 
mutants byDYRK2 pre-incubated with cold ATP prior to the radiolabeling reaction, and autorad 
(B) showing phosphorylation of PPARγ2 mutants 
 
A 
 
B  
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Figure 3.17: Graph (A) representing mol/mol stoichiometry of the phosphorylation of PPARγ2 
mutants byDYRK1B and autorad (B) showing phosphorylationof PPARγ2 mutants 
 
 
A 
 
B 
 
  DYRK1B aloneWTPPARγ2Ser8AlaThr75AlaSer112AlaThr296Ala 
DYRK1B 
PPARγ2 
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3.3 Discussion 
 
The phosphorylation of PPARγat Ser273 was reported to regulate the response 
of PPARγ to TZD treatment, and that it may be possible to use this property to 
design improved TZDs lacking the unwanted side effects of these drugs but 
maintaining beneficial therapeutic properties (Choi et al 2011). Alternatively 
manipulating CDK5 in adipose could have direct therapeutic benefits in 
diabetes. However, the sequence surrounding Ser273 of PPARγ is not a 
classical consensus for CDK5 targeting (Fig. 1.3). It lacks key basic residues, in 
particular at positions +2 and +3 relative to the phosphorylated serine (Dhavan 
and Tsai 2001). In addition, the evidence provided that phosphorylation of 
Ser273 was performed by CDK5 in vivo was relatively weak (Choi et al 2011) 
and thus required more detailed examination;the data presented in the paper 
used a generic CDK substrate antibody for most of the ser273data instead of a 
ser273 phospho-specific antibody, and the blots shown were not clear, with 
many bands present. 
 
My data suggests that PPARγ is a substrate for CDK5 in vitro, when it is 
complexed with p35 or p25, but that it is a better substrate for CDK5/p35 than 
CDK5/p25. Importantly, mutation of Ser273 to alanine did not affect the level of 
phosphorylation by either CDK5, indicating that this site was not a major 
phosphorylation siteforCDK5, at least in vitro. Mutation of each of the other 
serine or threonine phosphorylation sites on PPARγ (see Fig 1.3) did not cause 
a decrease in phosphorylation by CDK5, which may mean that CDK5 weakly 
phosphorylates more than one site, and this would require generation of PPARγ 
proteins with combinations of mutations to fully investigate. Alternatively 
phosphorylation site mapping by Mass Spectroscopy could identify which sites 
CDK5 phosphorylated in vitro, and development of phospho-specific antibodies 
to the different potential sites would allow quantification of relative 
phosphorylation in initial rate experiments. However a key finding from my 
phosphorylation analysis is that Ser273 seems not to be a major target for 
CDK5 in vitro. 
 
In order to develop a means to phosphorylate Ser273 to allow characterization 
of a phosphoSer273 antibody and analyse the effect of phosphorylation of this 
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site on PPARγ function I investigated whether any CDK5 related kinases could 
phosphorylate PPARγ in vitro.Any kinase that phosphorylates Ser273 would be 
potential ‘obesity regulated’ kinases and would regulate TZD efficacy. I found 
that DYRK1A, DYRK1B, DYRK2, ERK2, ERK8 and SAPK4 could phosphorylate 
PPARγ, although none of these kinases phosphorylated PPARγ at Ser273.  
 
ERK2 and ERK8 both phosphorylate PPARγ, but they appeared to do so at 
different sites. ERK2 has been previously documented to phosphorylate PPARγ 
at Ser112 (Adams et al 1997), but the site at which ERK8 phosphorylates 
PPARγremains unknown. ERK8 has a greater molecular mass than ERK2 and 
it is considered a distinct member of the ERK family (Abe et al 2002). 
Knowledge about the function of ERK8 is still limited (Strambiet al 2013), 
therefore it may interesting to investigate whether the PPARγsignalling cascade 
if truly a physiological target for this kinase (Gelmanet al 2005). 
 
DYRK2, DYRK1A and DYRK1B were all found to phosphorylate wild type 
PPARγ, and my preliminary data would suggest that DYRK2 can phosphorylate 
Ser112. The DYRK kinases prefer different consensus phosphorylation 
sequences, with DYRK2 preferring RXS/TP(Aranda, Laguna and Luna 2011); 
however it is also known that there are exceptions to the rule. Altered function 
of the DYRK family is linked to human disease, with DYRK1A expression being 
high in Downs Syndrome due to it lying on chromosome 21, DYRK1B being 
over-expressed in various types of cancer and DYRK2 expression being 
decreased in cancer (Aranda, Laguna and Luna 2011). This family has never 
previously been linked to the regulation of PPARγ however whether they 
regulate this transcription factor in vivoremains to be proven. 
 
SAPK2β is also known as p38β, and SAPK4 as p38δ.  The p38 kinases were 
already reported to phosphorylate PPARγ at Ser112 (Adams et al 1998). I found 
that SAPK2β phosphorylates PPARγrelatively poorly, compared to SAPK4. 
Experiments with the PPARγ mutants and using the phospho-specific 
antibodies suggested that phosphorylation by SAPK4 was most likely at 
Ser112, which agrees with the previously published data (Adams et 
al).Interestingly mutation of Thr296 to Ala also decreased phosphorylation by 
SAPK4which may suggest an additional novel regulation of PPARγ by this 
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kinase. However we cannot rule out that mutation of Thr296 interferes with 
phosphorylation of Ser112, either through hierarchical phosphorylation or by 
altering PPARγ interaction with SAPK4. This requires further investigation. 
 
As discussed earlier in this chapter, calculations for the degradation of the 
proteins had to be made for accurate stoichiometry of the incubation of the 
PPARγ mutant protein with the CMGC kinases shown to phosphorylate PPARγ. 
Having to account for degradation might not portray the results as accurately as 
full length mutated PPARγ protein incubations.  If there was more time on the 
project, the mutations of the PPARγ could be retried for a better yield of full 
length protein.  
 
The thesis lacks statistical power due to the availability and stability of the 
kinases, meaning that most experiments were only done twice, so instead 
statistical trends are talked about based on the range of the results. Had it been 
possible, an n=3 would have been used for the kinase assays so that standard 
deviation and the coefficient of variance could have been carried out. To 
improve statistical analysis and totest the null hypothesis if more data had been 
available, one way analysis of variance (ANOVA) could have been carried out, 
written with F stat [variance] with probability of result (P value), using SPSS or 
similar stats software to conduct tests.A post-hoc test could also have been 
done, as well as Tukey to test the mean difference, and chi-squared test to test 
whether the results happened by chance. 
 
For statistical analysis, sample size could have been used to detect any 
hypothetical difference. The larger a sample size, the more sure it can be that 
results are scientifically accurate and statistically significant.Aconfidence level, 
used in the sample size calculation shown below,reflects how sure you can be 
that the data lies within the confidence interval and is expressed as a 
percentage.The confidence interval is a plus or minus figure that shows 
quantification of the precision, represented as a margin of error. A 95% 
confidence level means you can be 95% certain of the data, and a 99% 
confidence level means you can be 99% certain; most laboratories use the 95% 
confidence level. For a given confidence level, the larger the sample size, the 
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smaller the confidence interval; however, the relationship is not linear, such that 
doubling the sample size does not halve the confidence interval. 
 
An example of an equation that calculates sample size and could have been 
used for statistical analysis includes: 
 
Z 2 * (p) * (1-p) 
  ss = 
c 2 
Where 
Z = Z value for confidence level (e.g. 1.96 for 95% confidence level)  
p = percentage picking a choice, expressed as decimal (0.5 used for sample 
size needed, in the case of a yes or no survey) 
c = confidence interval, expressed as decimal  (e.g. .04 = ±4) 
In terms of this thesis, a 95% confidence level would be used for the Z value 
and therefore a Z value of 1.96; the Z value is also known as the Z score and 
can be found using a Z score table. For the p value, 0.5 would be used as, 
similar to a yes or no survey, there is a yes or no answer with regards to is there 
a biological effect happening or not; in this case does phosphorylation of 
PPARγ get stopped by mutating it, or does phosphorylation still occur. The 
confidence interval is normally the standard deviation value, but as only the 
range was used due to n=2 results, the range would be used for the confidence 
interval. 
In summary, the work in this chapter questioned whether CDK5 would 
phosphorylate Ser273 of PPARγ, but as this work was entirely performed in 
vitro I decided to further investigate phosphorylation of PPARγ in cells and 
tissues and this forms the basis of the work presented in Chapter 4.
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Chapter 4 - Analysis of PPARγ Phosphorylation in Cells and 
Tissues 
 
4.1 Introduction and aims 
 
Although protein phosphorylation in vitro is a useful starting point for 
establishing kinase-substrate interactions it is always important to validate 
potential interactions in intact cells. Equally, there are mechanisms by which a 
‘bona fide’ target protein may not be a good substrate in vitro for a given kinase. 
For example if an additional protein or molecule was required to facilitate the 
interaction this would not be present in and in vitro assay and thus 
phosphorylation would not occur. Protein kinase B only becomes a substrate for 
PDK1 in the presence of the lipid phosphatidylinositol 3,4,5 trisphosphate and 
most protein kinase C isoforms require calcium and DAG to be active in vitro. 
Similarly, GSK3 requires its substrates to be pre-phosphorylated (primed) by an 
alternative kinase. Thus to investigate whether the phosphorylation of PPARγ 
by CDK5 required an unknown component I investigated the phosphorylation of 
PPARγ isoforms in intact cells and tissues. This required developing systems 
where I could express specific PPARγ isoforms along with the different CDK5 
complexes andalso the use of cell systems or tissues that were reported to 
express both of these enzymes or could be induced to express them. 
 
 
Aims of this Chapter: 
• To investigate phosphorylation of PPARγ isoforms when co-expressed 
with p35/CDK5 and p25/CDK5 
• To investigate phosphorylation of endogenous PPARγ in cells with or 
without CDK5 activity, and after exposure to stimuli related to obesity 
• To develop an inducible cell system to study the effect of phosphorylation 
of PPARγ on its function. 
• To investigate phosphorylation of PPARγ in rat adipose tissue isolated 
from animals fed normal chow or a high fat diet 
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4.2 Results 
 
4.2.1 Phosphorylation of PPARγ after expression in HEK-293 and HeLa cells 
As endogenous PPARγ is expressed at relatively low levels I attempted to 
develop a cell based recombinant system to study the phosphorylation of 
Ser273 of PPARγ. I was able to expressPPARγ (both isoforms and the S273A 
mutants) in the HEK-293 cells (Fig 4.1). However the recombinant PPARγ was 
not phosphorylated at Ser273, at least as assessed using our phospho-Ser273 
antibody or the commercial anti-Cdk substrate antibody (data not shown). 
Therefore I attempted to co-transfect the HEK-293 cells with PPARγ, CDK5 and 
either p35 or p25 (Fig 4.1). Multiple conditionsusing both calcium phosphate 
and lipofectamineprotocols failed to achieve triple transfections of CDK5, 
PPARγ and p25 or p35. Although FLAG-PPARγ expressed well in the HEK-293 
cells when co-transfected with CDK5 and p35 or p25 the expression of PPARγ 
(wild type or Ser273A) was lost; this made it impossible to establish whether co-
transfection of either CDK5 complex induced Ser273 phosphorylation of 
PPARγ  in this system. 
 
HeLa cells are reported to contain endogenous CDK5(Lenstra and Bloemendal 
1982) so these cells provided an opportunity to compare the effect of 
recombinant p35 and p25 expression on PPARγ phosphorylation, and they 
would potentially only require a double transfection of PPARγ with p25 or p35. 
However, althougheach protein expressed in these cells (Fig 4.2), this did not 
induce phosphorylation of PPARγ as measured by immunoblot using our 
phospho-Ser273 antibody or the commercial anti-Cdk substrate antibody (data 
not shown).  Therefore these cell systems did not provide a model system to 
allow analysis of PPARγ phosphorylation and comparison of p35 with p25. 
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Figure 4.1: Expression of FLAG-PPARγ1 and PPARγ2, wild type and ser273a mutant, in HEK-
293 cells is antagonized by co-transfection with CDK5 and p35. 
HEK-293 cells were co-transfected with 3 µg of pCMVvectors designed to express either wild 
type or S273A PPARγ with or without vectors designed to express CDK5, p25 and p35 as 
indicated. After 24h the cells were lysed and analysed by western blot with anti-FLAG (4.1A), 
anti-CDK5 and anti-p35 antibodies (4.1B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Expression of FLAG-PPARγ1 and PPARγ2 wild type and ser273a PPARγ alone, 
and co-transfection with p35 in HeLa cells 
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4.2.2. Stable inducible expression of PPARγ in HEK-293 cells. 
 
In an attempt to overcome the technical issues with transient transfection 
detailed above I stably inserted the cDNA for FLAG-PPARγ2 into the FT-293 
cell line (see Methods section). This cell system is designed to allow inducible 
expression of proteins of interest. I generated three clones of FT-293 cells 
containing PPARγ2 cDNA, namely LS1, LS2 and LS3. FT-293 LS1 showed the 
most consistent and robust expression of PPARγ as judged by immunoblot of 
lysates following induction (Fig 4.3) using both the flag antibody and PPARγ 
antibody; the FT-293LS1 cell line was used for all future experiments.  
 
During these initial expression tests, the samples were also probed with the 
PPARγ phospho-specific antibodies by immunoblot. Both the anti-pSer112 and 
anti-CDK substrate detected PPARγ2, but the anti-pSer273 antibody did not 
detect anything at the appropriate molecular weight after induction of PPARγ 
expression (Fig 4.3). 
 
The in vitro phosphorylation data (Chapter 3) indicated that DYRK and ERK2 
could phosphorylate PPARγ2 at Ser112. In an attempt to establish if either of 
these kinases was responsible for the observed phosphorylation of Ser112 in 
the FT293 LS1 cells they were incubated with harmine (DYRK inhibitor) or 
U0126 (inhibitor of ERK2 activation). The phosphorylation of PPARγ2 at Ser112 
was not altered by either inhibitor treatment, as judged using immunoblot with 
either the pSer112 or the Cdk substrate antibodies. U0126 efficacy was 
assessed by phosphorylation of ERK2 by immunoblot (Fig 4.4), but there are no 
good readouts for DYRK inhibition.  
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Figure 4.3: Analysis of lysates from the FT-PPARγ stable cell line by immunoblotwith PPARγ, 
flag, p-112, cdksubstate and p-Ser273 antibodies (MW ~58KD). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Analysis of PPARγ phosphorylation in FT-293LS1cellstreated with harmine and 
U0126, UI=uninduced, DMSO as a control (MW ~58KD). 
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4.2.3 Analysis of PPARγ in differentiated 3T3-L1s 
 
PPARγ expression is key to the differentiation of 3t3-L1 fibroblasts into 
adipocytes. Incubation of 3t3-L1 fibrobalsts with IBMX, dexamethasone and 
insulin over several days (see Methods section for details) promotes 
differentiation into adipocytes (Fig 4.5). This process can be monitored by Oil 
Red O staining of fat droplets (Figs 4.5 and 4.6).  
 
Figure 4.5: Images of 3t3L1 fibroblasts at different stages of differentiation into adipocyte like 
cellsstained with oil red O. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Images of 3t3L1 fibroblasts at different stages of induction to differentiate into 
adipocyte like cellsunder low and high light microscopy magnification. 
  
Control    Mid Differentiation Differentiated 
Undifferentiated       IBMX, Dex, Insulin         Post Insulin 
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PPARγ (both isoforms) and fatty acid binding protein (FABP) are both induced 
during differentiation and can be detected by immunoblot of cell lysates isolated 
during the process (Fig 4.7).  I detected CDK5 in undifferentiated and 
differentiated 3T3-L1 cells however I could not detect any p35 even after 
differentiation (Fig 4.7).  
 
I was unable to detect any phosphorylation of PPARγ, using immunoblot and 
the p-Ser112 and p-Ser273 antibodies (Fig 4.8). I also failed to detect any sign 
of phosphorylation using the Cdk5 substrate antibody, even after 
immunoprecipitation of PPARγ (Fig 4.9). 
 
Figure 4.7 Expression of PPARγ, FABP, p35 and CDK5 during differentiation of 3T3-L1 cells 
(control = undifferentiated, Mid Diff =day 2, ibmx+insulin, diff= differentiated, +ve control is 
recombinant PPARγ2) 
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Figure 4.8: Analysisof PPARγ phosphorylation by immunoblot before and after differentiation of 
3T3-L1 cells, with PPARγ p-Ser112 and p-Ser273 antibodies(control = undifferentiated, Day 
2=ibmx+insulin, Day4= insulin, Diff= differentiated) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: PPARγ was immunoprecipitatedfrom differentiated 3T3-L1 cells and analysed by 
immunoblot using a second PPARγ antibody and the anti-CDK substrate antibody. (+ve control= 
recombinant PPARγ1) 
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It remained possible that phosphorylation of Ser273 or Ser112 would only 
become apparent after specific cell stimuli (e.g. following hormone or nutrient 
challenge). Therefore I incubated differentiated 3T3-L1 cells with 500nM of 
palmitate to mimic obesity (Fig 4.10), 50ng of TNF-α, to mimic inflammation and 
157nM insulin to mimic the fed state (Fig 4.11). The concentrations of these 
agents were based on previously published studies (Choi et al 2011 and Kakriet 
al 2011). However there was no phosphorylation of PPARγ seen with any of 
these treatments of my cells (using any of the phosphospecific antibodies), 
although TNF-α treatment reduced IkB levels while insulin treatment induced 
the phosphorylation of ERK (Fig 4.11); if this was to be investigated further, a 
total ERK antibody would be used to interpret total ERK phosphorylation. 
 
Figure 4.10: Analysis of PPARγ phosphorylation by immunoblot, in differentiated 3T3 cells 
treated with 500nM palmitate, with PPARγ p-Ser112, p-Ser273 and CDK-substrate antibodies 
 
 
 
 
Control PalmitateEthanol                   
Anti-PPARγ  
Anti-pS112 
Anti-pS273 
Anti-CDK  
substrate 
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Figure 4.11: Analysis of PPARγphosphorylation by immunoblot in differentiated 3T3 cells 
treated with 50ng TNF-α or 167nm insulin for 1 hour, with  PPARγ, p-Ser112, p-Ser273, CDK-
substrate, IKB and p-ERK antibodies (MW PPARγ1 ~55 and  PPARγ2 ~58kd, control- vehicle 
treated) 
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4.2.4 PPARγ phosphorylation in rat adipose tissue. 
 
My studies had been initiated following the report of obesity-induced 
phosphorylation of PPARγ at Ser-273. All of my in vitro and cell based work 
questioned whether PPARγ was phosphorylated at Ser273. However as these 
were all relatively artificial systems I decided to investigate whether I could 
observe any alterations in Ser273 phosphorylation, CDK5 activation or p35 
modification following high fat feeding of rats. The rat adipose samples were 
provided from a study performed in our laboratory looking at high fat diet effects 
on insulin sensitivity and behaviour. The high fat diet increased BMI and 
generated insulin resistance within the 10 weeks of the study (see Methods for 
details). I therefore attempted to extract PPARγ from adipose tissue and 
compare phosphorylation between the obese and the lean animals. However, 
PPARγ was almost impossible to extract from adipose (both standard chow and 
high fat fed rat adipose tissue). I used multiple different protocols including 
different extraction buffers (RIPA, triton-x-100, hepes buffer and solvent 
extraction methods) but in no case was I able to robustly isolate PPARγ (Figs 
4.12, Fig 4.13 and Fig 4.14).  
 
When RIPA buffer was used,actin could be detectedbut not PPARγ (Fig 4.12).I 
also tried toimmunoprecipitate the PPARγin order to enrich and concentrate it 
priorto immunoblot. This was performed after extraction in triton-x-100 lysis 
buffer as the RIPA buffer contains SDS. Recombinant PPARγ extracted from 
HEK-293 cells was used to confirm the immunoprecipitation and immunoblot 
was working but immunopreciptationfrom the tissue lysates did not enhance the 
PPARγ signal (Fig 4.13). 
 
Data from two further attempts to extract PPARγ are shown in Fig 4.14. Firstly a 
PPARγ blot following an immunoprecipitation performed on adipose tissue 
lysates extracted in hepes buffer, and an immunoblot of adipose tissue lysates 
generated by solvent extraction. FABP was detectable in the solvent extractions 
demonstrating that protein was being extracted, however PPARγ could not be 
found. The solvent extractions generate an insoluble protein fraction (disc) and 
an aqueous soluble fraction but PPARγ was not readily detectable in either. 
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The lysates were also probed with the PPARγ phospho-specific antibodies 
despite the lack of detection of PPARγ and perhaps not surprisingly there was 
no evidence found for Ser273 phosphorylation in either the lean or obese tissue 
(data not shown). 
 
In summary despite multiple approaches I was not able to generate solid 
evidence that PPARγ phosphorylation occurs in response to high fat feeding, 
and indeed I was not able to detect CDK5 or p35 in rat adipose tissue (data not 
shown). 
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4.3 Discussion 
 
I have analysedvarious cell lines for phosphorylation of PPARγ at Ser273 site, 
including 3t3-L1 adipocytes where I was able to detect endogenous PPARγ but 
not phosphorylation. Over-expression of recombinant human PPARγ transiently 
in HEK-293 or HeLa cells also failed to provide evidence that phosphorylation of 
PPARγ at Ser273 occurs. In addition stable expression ofPPARγ in HEK-293 
cells generated sufficient quantities of PPARγ to allow visualization of Ser112 
phosphorylation butI was unable to detect phosphorylation at Ser273. Attempts 
to stimulate phosphorylation using palmitate, TNF-αor insulin were also 
unsuccessful.Of course all of these experiments relied on a phospho-Ser273 
antibody which we have not been able to characterize against the intact PPARγ, 
as we have not identified a protein kinase that will phosphorylate this site. The 
antibody does recognize a peptide based on the phosphorylated sequence 
surrounding the Ser273 site of PPARγ but it remains possible that this antibody 
is not sensitive enough to detect the phosphorylation.  
 
I had one attempt at mapping the phosphorylation of recombinant PPARγfrom 
HEK-293 cells by mass spectroscopy (in collaboration with Dr Lamont, 
University of Dundee), however the results of this study were inconclusive and 
should really be performed on endogenous PPARγ from adipose, which awaits 
the development of improved extraction protocols. However, should extraction 
become possible, then the peptide mapping of PPARγ may be the most 
appropriate approach to definitively assess whether Ser273 is truly 
phosphorylated in vivo. 
 
It is also worth reiterating that although I was able to extract housekeeping 
proteins such as actin and FABP from adipose tissue I was not able to detect 
CDK5 nor p35 or p25, even after high fat feeding. Taken together with my in 
vitro phosphorylation studies and the analysis of PPARγ phosphorylation in 
cells and tissues these resultsdisagree with the hypothesis that initiated my 
thesis; namely that obesity induces p35 modification, generation of p25, 
activation of CDK5 and phosphorylation of PPARγ at Ser273. 
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Although the results obtained during my research are in conflict with the 
published data by Professor Bruce Spiegelman,my data is consistent with that 
of Dhavan (2001), who reported no changes in phosphorylation of PPARγ when 
any of the proline-directed sites were mutated. My data was also in agreement 
with previously published data indicating that Ser112 was 
aregulatablephosphorylation site on PPARγ (Adams et al 1997), and I show 
preliminary evidence that Thr296 is worthy of further investigation as 
phosphorylation site involved in PPARγ regulation. My data could have 
conflicted with Professor Bruce Spiegelman’s due to the different antibodies 
used, the confliction with the data already produced by previous groups, or the 
fact that CDK5 does not contain a known consensus sequence for the 
phosphorylation of PPARγ. 
Finally, much of the work presented here is negative; however it questions the 
need for development of new drugs that target this modification. The tools 
generated during my studies (phospho-specific antibody and mutant PPARγ 
constructs and proteins) provide opportunities to broaden the analysis of 
PPARγ regulation by phosphorylation at sites other than Ser273 and by kinases 
other than CDK5. 
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